Skip to content
vigabatrin.org

Sources

These are the 157 sources this site cites: peer-reviewed studies found through PubMed, FDA prescribing information, and federal handling guidance. Each entry was checked against its PubMed record or the current label.

Key sources

Liquid vs powder vs tablets: dosing accuracy, preparation, caregiver burden

  • Gibson R, Klima R, Van Horn J. Liquid Medication Dosing Errors: Comparison of a Ready-to-Use Vigabatrin Solution to Reconstituted Solutions of Vigabatrin Powder for Oral Solution. Adv Ther. 2025;42(3):1484-1493. PMID 39899223 · DOI 10.1007/s12325-024-03089-0 · PMC11868180 (Epub Feb 2025; often cited as 2024) PubMedDOI

    Crossover usability study with 30 lay users: 15 experienced powder caregivers and 15 syringe-naïve users. Each prepared one 1,125 mg dose of RTU surrogate solution (11.25 mL) and one of Sabril powder (22.5 mL). RTU: 30/30 within ±5%. Powder: 23/30 (77%) within ±10%. Naïve users: 13/15 within ±10%. Experienced users: 10/15 within ±10%; all experienced users were within ±3% with RTU. (Full text) Powder dose range was 425–1,390 mg (−62.2% to +23.6%). About 70% of RTU doses were within 2% of target, against 20% of powder doses. Mean % of target was 99% (95% CI 98–100) for RTU and 90% (84–96) for powder. Adjusted absolute deviation was 12 mg for RTU and 122 mg for powder. RTU was more accurate (p<0.01) and less variable (p<0.0001). COI: authors employed by Pyros (the Vigafyde NDA holder). The limitations section names single-dose design, no RTU assay, written instructions only, and low power. (Full text) The RTU arm used a surrogate solution that "mirrored the physicochemical and viscosity characteristics of VIGAFYDE". RTU dose was "calculated using the theoretical concentration of vigabatrin (100 mg/mL) multiplied by the volume of solution delivered" (volume from weight and density). Powder doses used volume × each solution's HPLC-assayed concentration. License (PMC record): open access under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).

  • Zachman M, Gong L, An L, Halvorsen MB. Dissolution and stability of vigabatrin powder in water, fruit juice, milk, and infant formula. Epilepsy Behav Rep. 2025;31:100816. PMID 40838171 · DOI 10.1016/j.ebr.2025.100816 PubMedDOI

    Vigadrone powder reconstituted in water, apple juice, whole milk or infant formula and stored at 2–8 °C in capped glass. All samples met USP 95.0–105.0% potency and impurity criteria at 0, 24 and 48 h. The Vigadrone label itself says to reconstitute in water only and discard unused solution. Authors are from Upsher-Smith/Aucta. (Cuts against a "powder is unstable" framing.)

  • Yin HS, Parker RM, Sanders LM, et al. Liquid Medication Errors and Dosing Tools: A Randomized Controlled Experiment. Pediatrics. 2016;138(4):e20160357. PMID 27621414 · DOI 10.1542/peds.2016-0357 PubMedDOI

    2,110 parents each measured 9 doses. 84.4% made at least one error (>20% deviation) and 21.0% made at least one large error (>2× dose). Cups were worse than syringes (aOR 4.6, 95% CI 4.2–5.1), especially for small doses. Teaspoon-only labels were worse than mL-only (aOR 1.2).

  • Yin HS, Parker RM, Sanders LM, et al. Pictograms, Units and Dosing Tools, and Parent Medication Errors: A Randomized Study. Pediatrics. 2017;140(1):e20163237. PMID 28759396 · DOI 10.1542/peds.2016-3237 PubMedDOI

    491 parents. 83.5% made at least one error and 29.3% made at least one large (>2×) error. Matching the syringe size to the dose volume had the biggest effect. For a 2 mL dose, a 5 mL syringe beat a 10 mL syringe (aOR 0.3). For 7.5 mL, a 10 mL syringe was best, avoiding multiple refills (5 mL vs 10 mL syringe aOR 4.0). (Relevant: larger powder volumes, such as 22.5 mL, may need several syringe-fulls.)

  • Yin HS, Mendelsohn AL, Wolf MS, et al. Parents' medication administration errors: role of dosing instruments and health literacy. Arch Pediatr Adolesc Med. 2010;164(2):181-186. PMID 20124148 · DOI 10.1001/archpediatrics.2009.269 PubMedDOI

    302 parents measuring a 5 mL dose. Accuracy was 30.5% with a printed cup and 50.2% with an etched cup, against >85% with oral syringes, droppers or spoons. Cup vs syringe error aOR was 26.7 (printed cup). Limited health literacy raised error risk (aOR 1.7).

  • Yin HS, Dreyer BP, Ugboaja DC, et al. Unit of measurement used and parent medication dosing errors. Pediatrics. 2014;134(2):e354-e361. PMID 25022742 · DOI 10.1542/peds.2014-0395 PubMedDOI

    287 ED parents. 39.4% made an error measuring the intended dose and 41.1% erred on the prescribed dose. Teaspoon/tablespoon units roughly doubled the odds of error compared with mL-only (aOR 2.3).

  • Yin HS, Neuspiel DR, Paul IM, et al. Preventing Home Medication Administration Errors. Pediatrics. 2021;148(6):e2021054666. PMID 34851406 · DOI 10.1542/peds.2021-054666 PubMedDOI

    AAP policy statement. Home administration errors are common, "especially when liquid preparations are used and complex medication schedules"; "children with chronic conditions are disproportionately affected." Recommends dosing-tool provision, teach-back and pictograms.

  • Arenas-López S, Gurung K, Tibby SM, et al. Accuracy of enteral syringes with commonly prescribed paediatric liquid medicines. Arch Dis Child. 2017;102(7):655-659. PMID 28235838 · DOI 10.1136/archdischild-2016-312492 PubMedDOI

    In vitro test of 10 drugs, volumes 0.05–5 mL, 1–5 mL syringes. Small volumes were inaccurate across all syringe sizes and brands, and 1 mL syringes were inaccurate at ≤0.1 mL. Authors suggest manufacturers revise formulation concentrations. (Double-edged for a more concentrated product; see "against" list.)

  • Walsh J, van Riet-Nales D, Hermans E, et al. European Paediatric Formulation Initiative workshop report: Improving the administration of oral liquid medicines in paediatrics using dosing syringes and enteral accessories. Eur J Pharm Biopharm. 2020;151:91-97. PMID 32289491 · DOI 10.1016/j.ejpb.2020.04.007 PubMedDOI

    Expert workshop: spoons and cups are unsuitable for small volumes, and syringes are better. Accuracy for very small volumes in young children "is still not sufficiently ensured."

  • Neves I, Auxtero MD. Dosing Accuracy of Oral Extemporaneous Suspensions of Antibiotics: Measuring Procedures and Administration Devices. Pharmaceutics. 2021;13(4):528. PMID 33920192 · DOI 10.3390/pharmaceutics13040528 PubMedDOI

    40 pharmacy students measured reconstituted azithromycin. Most ignored "shake before use". Spoons under-delivered and syringes over-delivered compared with the reference (p<0.001). This shows preparation-step errors with caregiver-reconstituted liquids. Note: azithromycin is a suspension; vigabatrin powder dissolves into a solution.

  • Watson C, Webb EA, Kerr S, et al. How close is the dose? Manipulation of 10 mg hydrocortisone tablets to provide appropriate doses to children. Int J Pharm. 2018;545(1-2):57-63. PMID 29705101 · DOI 10.1016/j.ijpharm.2018.04.054 PubMedDOI

    Naïve users got only 57–58% of manipulated-tablet doses within 20% of target. 74.1% of parents/carers (n=27) managed it. Conclusion: the lack of age-appropriate formulations puts children at risk of sub-optimal dosing. (Proxy evidence for splitting or crushing vigabatrin tablets; not vigabatrin-specific.)

  • Eserian JK, Lombardo M, Chagas JR, Galduróz JCF. Actual Versus Expected Doses of Half Tablets Containing Prescribed Psychoactive Substances: A Systematic Review. Prim Care Companion CNS Disord. 2018;20(1):17r02211. PMID 29469240 · DOI 10.4088/PCC.17r02211 PubMedDOI

    13 studies, including anticonvulsants. Splitting was satisfactory in only 55% of cases, and uneven division risks under- or overdosing.

  • Blackmer AB, Fox D, Arendt D, et al. Perceived Versus Demonstrated Understanding of the Complex Medications of Medically Complex Children. J Pediatr Pharmacol Ther. 2021;26(1):62-72. PMID 33424502 · DOI 10.5863/1551-6776-26.1.62 PubMedDOI

    156 medically complex children (76.9% neurologically impaired; median 8 medications). Perceived confidence was 81–99%. Only 54.8% correctly measured two doses and only 40.4% knew complete dosing parameters.

  • Velarde-García JF, Güeita-Rodríguez J, Jiménez-Antona C, et al. The impact of developmental and epileptic encephalopathies on families: a qualitative study. Eur J Pediatr. 2024;183(9):4103-4110. PMID 38965081 · DOI 10.1007/s00431-024-05677-2 PubMedDOI

    21 parents of children with DEEs. Themes were couple strain, impact on siblings and grandparents, and parents cutting or quitting work to provide care. (General caregiver-burden context; not IS- or formulation-specific.)

  • Sarpatwari A, Brown BL, McGraw SA, et al. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Netw Open. 2022;5(1):e2144386. PMID 35050352 · DOI 10.1001/jamanetworkopen.2021.44386 PubMedDOI

    63 interviewees, including 10 vigabatrin patients and 4 vigabatrin caregivers. REMS reassured people but created access burdens, such as travel to certified prescribers or pharmacies, and educational materials were hard to understand.

  • Sarpatwari A, Brown BL, McGraw SA, et al. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. PLoS One. 2023;18(7):e0288008. PMID 37410756 · DOI 10.1371/journal.pone.0288008 PubMedDOI

    31 physicians, 6 of them vigabatrin prescribers. Physicians understood REMS but saw limited effect on practice and raised concerns about administrative burden.

  • ClinicalTrials.gov NCT02220114, Orphelia Pharma. Acceptability Study of a New Paediatric Form of Vigabatrin… Completed, n=38. Source

    The sponsor's registry text says Sabril granules are "not adapted for administration to infants when a fraction of the sachet is needed. Manual splitting of the sachet or lengthy and error-prone dilutions are often required." This is a sponsor statement (EU soluble-tablet developer), not a published result. No linked publication was found on PubMed. ---

FDA label and regulatory facts

  • Drugs@FDA (openFDA API): NDA 217684, VIGAFYDE (vigabatrin) oral solution 100 mg/mL, sponsor Pyros Pharms; original approval 2024-06-17. Source

    Drugs@FDA (openFDA API): NDA 217684, VIGAFYDE (vigabatrin) oral solution 100 mg/mL, sponsor Pyros Pharms; original approval 2024-06-17.

  • Drugs@FDA: NDA 020427 SABRIL tablet 500 mg and NDA 022006 SABRIL for oral solution 500 mg/packet, Lundbeck. Both approved 2009-08-21. Source

    Drugs@FDA: NDA 020427 SABRIL tablet 500 mg and NDA 022006 SABRIL for oral solution 500 mg/packet, Lundbeck. Both approved 2009-08-21.

  • Drugs@FDA (openFDA): numerous ANDAs for vigabatrin for oral solution 500 mg/packet and tablets 500 mg. Examples: VIGADRONE ANDA 210196 (approved 2018-06-21; DailyMed labeler now Upsher-Smith); VIGPODER ANDA 214961 (Pyros; openFDA product: vigabatrin 500MG/PACKET, dosage form "FOR SOLUTION", route oral, TE code AA, i.e. a powder for oral solution; original approval 2022-06-24; no current DailyMed SPL found under the name Vigpoder); Teva, Amneal, Dr. Reddy's, Zydus and others. VIGAFYDE was the only vigabatrin "SOLUTION" (ready-to-use) dosage form in the results. Source

    Drugs@FDA (openFDA): numerous ANDAs for vigabatrin for oral solution 500 mg/packet and tablets 500 mg. Examples: VIGADRONE ANDA 210196 (approved 2018-06-21; DailyMed labeler now Upsher-Smith); VIGPODER ANDA 214961 (Pyros; openFDA product: vigabatrin 500MG/PACKET, dosage form "FOR SOLUTION", route oral, TE code AA, i.e. a powder for oral solution; original approval 2022-06-24; no current DailyMed SPL found under the name Vigpoder); Teva, Amneal, Dr. Reddy's, Zydus and others. VIGAFYDE was the only vigabatrin "SOLUTION" (ready-to-use) dosage form in the results.

  • VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source

    Indication: monotherapy for IS, 1 month to 2 years, "for whom the potential benefits outweigh the potential risk of vision loss." No rCPS indication; "not approved for use in adults." Concentration/admin: 100 mg/mL; "does not require additional reconstitution or dilution." Given orally or via G-tube; with GJ tubes, use the G-port. Flush with water after. With or without food. Use a calibrated device, not household spoons. Dosing: start 50 mg/kg/day (25 mg/kg BID). Titrate by 25–50 mg/kg/day every 3 days to a maximum of 150 mg/kg/day (75 mg/kg BID). Table 1 volumes, examples: 3 kg 0.75 mL BID start / 2.25 mL BID max; 5 kg 1.25 / 3.75 mL; 10 kg 2.5 / 7.5 mL BID. Switching (§2.3): Vigafyde needs a smaller volume than other vigabatrin products (100 vs 50 mg/mL). Verify volume when switching. How supplied/storage: 150 mL HDPE bottle (NDC 80789-003-15). Clear, peppermint-flavored, sweetened with sucralose. Inactives: methylparaben, propylparaben, peppermint flavor, purified water, sucralose. Store unopened at 20–25 °C. After opening, keep at 2–30 °C and discard 90 days after first opening. Efficacy basis (§14): "based upon a comparison of the compositional differences between vigabatrin for oral solution and VIGAFYDE". Boxed warning: permanent bilateral concentric visual field constriction; may decrease acuity. Risk rises with dose and cumulative exposure, and no dose is risk-free. Available only through the Vigabatrin REMS. Vision monitoring: baseline (no later than 4 weeks after starting), at least every 3 months on therapy, and about 3–6 months after stopping. REMS (§5.2): prescribers certified, patients enrolled, pharmacies certified. www.vigabatrinREMS.com, 1-866-244-8175. Renal: no infant dose-adjustment data. PK in adults: mild impairment AUC +30%; moderate AUC 2×; severe AUC 4.5×. Other W&P: MRI changes in infants (22% vigabatrin vs 4% other therapies, n=205); somnolence 6% vs 5% placebo and fatigue 10% vs 7% (pediatric pooled); weight gain ≥7% in 47% vs 19% (pediatric pooled); taper to stop (25–50 mg/kg every 3–4 days in the IS study). G-tube wording (§2.1): "Administer VIGAFYDE orally or via gastrostomy (G) tube. Doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. After G-tube administration, flush with water." §17 tells prescribers to give caregivers instructions on "how to flush the tube after administration." Storage wording (§16): "Store unopened bottles at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F)". After opening, 2–30 °C; "Discard the unused portion 90 days after first opening." Discontinuation (§2.4, §5.5): "Avoid abrupt withdrawal" (§2.4). "As with all antiepileptic drugs, VIGAFYDE should be withdrawn gradually… if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. Caregivers should be told not to suddenly discontinue VIGAFYDE therapy" (§5.5). IS-study taper: 25 to 50 mg/kg every 3 to 4 days (§2.4). Suicidal behavior (§5.11): titled "Suicidal Behavior and Ideation with Unapproved Use in Adolescents and Adults"; "VIGAFYDE is not approved for use in adolescents or adults. Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in adolescents and adults." Mechanism (§12.1): same wording as label-sabril-tablet-2021 §12.1 ("believed to be" irreversible GABA-T inhibition; "increased levels of GABA in the central nervous system").

  • SABRIL (vigabatrin) for oral solution prescribing information, revised 10/2021. Source

    Indications: rCPS adjunct from age 2 (not first-line); IS monotherapy 1 month–2 years. Reconstitution (§2.5): "Empty the entire contents of each 500 mg packet into a clean cup, and dissolve in 10 mL of cold or room temperature water per packet." Final concentration 50 mg/mL. Table 3: dose 0–500 mg = 1 packet + 10 mL; 501–1000 mg = 2 packets + 20 mL; 1001–1500 mg = 3 packets + 30 mL. "Discard the resulting solution if it is not clear… Each individual dose should be prepared and used immediately. Discard any unused portion." 3 mL or 10 mL oral syringes are supplied separately by the pharmacy. IS volumes (Table 2, 50 mg/mL): 3 kg 1.5 mL BID start / 4.5 mL max; 10 kg 5 / 15 mL; 16 kg 8 / 24 mL BID. Counseling (§17): "Physicians should confirm that caregivers(s) understand how to mix SABRIL for oral solution and to administer the correct dose." Storage: 20–25 °C; packages of 50 packets. Same document as the tablet label: this setid carries the combined SABRIL tablets + for oral solution prescribing information (identical text to label-sabril-tablet-2021, including the boxed warning "WARNING: PERMANENT VISION LOSS", REMS-only availability (§5.2), §5.5 suicidal behavior and §5.6 withdrawal). See label-sabril-tablet-2021 for wording. (Derived from the label, not a study: a 5 kg infant starting at 125 mg BID uses one 500 mg packet per dose and discards 7.5 mL, i.e. 375 mg, twice daily.)

  • SABRIL (vigabatrin) tablets prescribing information, revised 10/2021. Source

    500 mg film-coated tablet, scored, bottles of 100. rCPS adults (≥17): start 1,000 mg/day (500 mg BID), increase by 500 mg weekly, recommended 3,000 mg/day. 6,000 mg/day adds no benefit and more adverse events. rCPS pediatrics (2–16 y), Table 1, total daily dose start → maintenance: 10–15 kg 350 → 1,050 mg; >15–20 kg 450 → 1,300 mg; >20–25 kg 500 → 1,500 mg; >25–60 kg 500 → 2,000 mg; >60 kg dosed as adults. Withdraw if no substantial benefit within 3 months (rCPS) or 2–4 weeks (IS). Renal (≥2 y and adults): CLcr >50–80 reduce dose 25%; >30–50 reduce 50%; >10–30 reduce 75%. No infant data. "Bioequivalence has been established between the oral solution and tablet formulations." Vision: "Based upon adult studies, 30 percent or more of patients can be affected"; severe cases can mean tunnel vision within 10°. rCPS trials: Study 1 (n=174) ≥50% responders 51% at 3 g/day and 53% at 6 g/day vs 9% placebo. PK: half-life 5.7 h (infants), 6.8 h (3–9 y), 9.5 h (10–16 y), 10.5 h (adults). About 95% of radiolabel recovered in urine, 80% of it parent drug. Tmax about 1 h (children/adults) and 2.5 h (infants). Combined label: this SPL is the joint "SABRIL (vigabatrin) tablets, for oral use / SABRIL (vigabatrin) for oral solution" prescribing information (same text as label-sabril-powder-2021). Indications (§1, Highlights): "Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; SABRIL is not indicated as a first line agent". §1.1 full text: "adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss." §1.2: "monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss." IS dosing form (§2.3): the IS section doses by volume: "Table 2 provides the volume of the 50 mg/mL dosing solution that should be administered as individual doses in infants". §2.1: the regimen "depends on the indication, age group, weight, and dosage form (tablets or for oral solution)". The label does not state in so many words that tablets may not be used for IS. Boxed warning: "WARNING: PERMANENT VISION LOSS". "Vision assessment is recommended at baseline (no later than 4 weeks after starting SABRIL), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy." Available "only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program" (§5.2). Stop if no benefit, tied to vision risk: boxed warning: "Because of the risk of visual loss, SABRIL should be withdrawn from patients with refractory complex partial seizures who fail to show substantial clinical benefit within 3 months of initiation and within 2-4 weeks of initiation for patients with infantile spasms, or sooner if treatment failure becomes obvious." §2.2 repeats the 3-month rule and cross-refers to §5.1 (Permanent Vision Loss). Withdrawal (§2.1, §5.6, §9.3, §17): "If a decision is made to discontinue SABRIL, the dose should be gradually reduced" (§2.1). "As with all AEDs, SABRIL should be withdrawn gradually. However, if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. Patients and caregivers should be told not to suddenly discontinue SABRIL therapy" (§5.6). "As with all AEDs, vigabatrin should be withdrawn gradually to minimize increased seizure frequency" (§9.3 Dependence). Taper schedules used in trials (§2.2, §2.3, §5.6): adults with CPS, "decreasing the daily dose 1000 mg/day on a weekly basis until discontinued"; pediatric CPS, "decreasing the daily dose by one third every week for three weeks"; IS, "decreasing the daily dose at a rate of 25 mg/kg to 50 mg/kg every 3 to 4 days." Suicidal behavior (§5.5): "Antiepileptic drugs (AEDs), including SABRIL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." Pooled analysis of 199 trials of 11 AEDs: adjusted RR 1.8 (95% CI 1.2–2.7); 0.43% vs 0.24%, about one extra case per 530 patients treated. Mechanism (§12.1): "The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system." Duration of effect "is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug". Elimination (§12.3): "Vigabatrin is not significantly metabolized; it is eliminated primarily through renal excretion." (With the radiolabel data above: about 95% recovered in urine over 72 h, about 80% of it parent drug.)

  • VIGADRONE (vigabatrin) for oral solution, revised 12/2025, Upsher-Smith. Source

    Same reconstitution as Sabril: 10 mL water per 500 mg packet, 50 mg/mL, prepare each dose immediately, discard any unused portion. Cartons of 50 packets. Boxed warning "WARNING: PERMANENT VISION LOSS", same vision-monitoring schedule (baseline no later than 4 weeks, at least every 3 months, about 3 to 6 months after stopping); "available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program." Withdrawal (§5.6): "As with all AEDs, VIGADRONE should be withdrawn gradually… Patients and caregivers should be told not to suddenly discontinue VIGADRONE therapy." Same trial taper schedules as Sabril (adult CPS 1000 mg/day weekly; pediatric CPS one third weekly for three weeks; IS 25 to 50 mg/kg every 3 to 4 days).

  • Vigabatrin REMS: www.vigabatrinREMS.com (as cited in both labels). Requirements as summarized under label-vigafyde-2025 §5.2. (The REMS website itself was not fetched; requirements are cited from the FDA labels.) Source

    Vigabatrin REMS: www.vigabatrinREMS.com (as cited in both labels). Requirements as summarized under label-vigafyde-2025 §5.2. (The REMS website itself was not fetched; requirements are cited from the FDA labels.)

NIOSH hazardous drug status and handling

  • NIOSH. NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. Ovesen JL, Sammons D, Connor TH, et al. DHHS (NIOSH) Publication No. 2025-103, December 2024 (supersedes 2016-161). DOI 10.26616/NIOSHPUB2025103 · DOI

    Vigabatrin: Table 2, AHFS 28:12.92 (anticonvulsants, miscellaneous), not a biologic, "Only Developmental and/or Reproductive Hazard" = Yes. Change log: "Moved from Table 3 to Table 2". In the 2016 list, Table 3 held non-antineoplastic drugs with only reproductive or developmental hazard; the 2024 list merged these into Table 2 with a flag. Table 2 definition: drugs that meet the NIOSH hazardous-drug definition, have no manufacturer's special handling information (MSHI), and are not NTP "known human carcinogen" or IARC Group 1/2A.

  • NIOSH. Managing Hazardous Drug Exposures: Information for Healthcare Settings. Hodson L, Ovesen J, Couch J, et al. DHHS (NIOSH) Publication No. 2023-130, April 2023. DOI 10.26616/NIOSHPUB2023130 DOI

    "Crushing tablets or opening capsules should be avoided, and liquid formulations should be used whenever possible." "Cutting, crushing, or otherwise manipulating tablets and capsules will increase the potential for exposure of workers." Table of Control Approaches (healthcare workers): Administering intact tablets: single gloves. Crushing or manipulating tablets: ventilated engineering control, double chemo gloves, gown, and N95 if done outside the control; consider a pill pouch. Administering an oral liquid by mouth or feeding tube: double gloves and gown; eye protection if splash is likely. Even reproductive-only drugs warrant facility risk management for all staff, not only those who are pregnant.

  • USP. USP <800> FAQs, updated January 21, 2026. Source

    <800> became official 1 Dec 2019 and compendially applicable (as far as <795>/<797> apply) on 1 Nov 2023. For HDs other than active pharmaceutical ingredients (APIs) and NIOSH Table 1 antineoplastics, facilities may do an assessment of risk by drug and dosage form. "Crushing HD tablets or opening capsules may have more risk of exposure than dispensing tablets without further manipulation." Example mitigations include unit-dose packaging and reassigning pregnant staff. <800> covers healthcare personnel and settings, not home caregivers. Relevance to vigabatrin: pharmacy or clinic staff who crush tablets or prepare doses should follow a vigabatrin-specific assessment of risk. ---

Efficacy

  • Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57(8):1416-1421. PMID 11673582 · DOI 10.1212/wnl.57.8.1416 PubMedDOI

    Low dose (18–36 mg/kg/day) vs high dose (100–148 mg/kg/day). Responders: 8/75 on low dose vs 24/67 on high dose (p<0.001). Faster response with TSC (p<0.001). 9 discontinued for adverse events.

  • Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol. 2010;25(11):1340-1347. PMID 20404353 · DOI 10.1177/0883073810365103 PubMedDOI

    Modified ITT n=221. Video-EEG-confirmed spasm cessation: 15.9% (17/107) high dose vs 7.0% (8/114) low dose (p=0.0375). 23% relapsed during follow-up, and 72% of those regained spasm freedom. This is the label's IS "Study 1".

  • Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364(9447):1773-1778. PMID 15541450 · DOI 10.1016/S0140-6736(04)17400-X17400-X) PubMedDOI

    n=107 (TSC excluded). No spasms on days 13–14: hormonal 73% (40/55) vs vigabatrin 54% (28/52); difference 19% (p=0.043). Adverse events 55% vs 54%.

  • Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4(11):712-717. PMID 16239177 · DOI 10.1016/S1474-4422(05)70199-X70199-X) PubMedDOI

    Spasm-free at 12–14 months: hormone 75% vs vigabatrin 76% (p=0.82). Vineland Adaptive Behavior Scales (VABS) score was similar overall. With no identified cause, VABS was 88.2 (hormone) vs 78.9 (vigabatrin), p=0.025.

  • Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010;95(5):382-386. PMID 20457702 · DOI 10.1136/adc.2009.160606 PubMedDOI

    77 traced. Overall VABS was not significantly different (median 60 vs 50; p=0.091). No identified cause: 96 vs 63 (p=0.033) favoring hormones.

  • O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia. 2011;52(7):1359-1364. PMID 21668442 · DOI 10.1111/j.1528-1167.2011.03127.x PubMedDOI

    Each step up in lead-time category was linked to a 3.9-point lower VABS score at 4 years (p=0.014).

  • O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33-42. PMID 27838190 · DOI 10.1016/S1474-4422(16)30294-030294-0) PubMedDOI

    n=377. No spasms days 14–42: combination 72% (133/186) vs hormone alone 57% (108/191); difference 15.0% (95% CI 5.1–24.9; p=0.002). Vigabatrin minimum 100 mg/kg/day.

  • O'Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(10):715-725. PMID 30236380 · DOI 10.1016/S2352-4642(18)30244-X30244-X) PubMedDOI

    VABS at 18 months was no different (73.9 vs 72.7; p=0.55), and epilepsy rates were similar (30.0% vs 29.2%). Early spasm control was linked to VABS 79.1 vs 63.2 (p<0.001). Longer lead time was linked to lower VABS (p<0.001).

  • Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;(6):CD001770. PMID 23740534 · DOI 10.1002/14651858.CD001770.pub3 PubMedDOI

    18 RCTs, 916 patients, mostly poor methodology. Hormones resolve spasms faster and in more infants than vigabatrin. "If prednisolone or vigabatrin is used, high dosage is recommended. Vigabatrin may be the treatment of choice in tuberous sclerosis."

  • Xu Z, Gong P, Jiao X, et al. Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. Epilepsia Open. 2023;8(2):268-277. PMID 36740237 · DOI 10.1002/epi4.12703 PubMedDOI

    5 RCTs: vigabatrin monotherapy was inferior to hormonal monotherapy (OR 0.37, 95% CI 0.20–0.67). Observational studies agree (OR 0.61). Vigabatrin works better in TSC than other causes (OR 5.59, 95% CI 2.17–14.41). Combination vs hormone: OR 0.75 (95% CI 0.09–6.45, not significant).

  • Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016;79(3):475-484. PMID 26704170 · DOI 10.1002/ana.24594 PubMedDOI

    230 infants, 22 US centers. Sustained 3-month response: ACTH 55%, oral steroids 39%, vigabatrin 36%, non-standard 9% (p<0.001).

  • Yuskaitis CJ, Mytinger JR, Baumer FM, et al. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Neurology. 2022;99(22):e2494-e2503. PMID 36038267 · DOI 10.1212/WNL.0000000000201232 PubMedDOI

    395 infants. 43% remitted within 2 weeks, and 81% of those within week 1. Median time to response: vigabatrin 3 days (IQR 1–6), ACTH 4, steroids 3. Non-responders at 1 week should be reassessed immediately. (Supports accurate dosing during the critical first-week titration.) Design: prospective observational cohort. The National Infantile Spasms Consortium (Pediatric Epilepsy Research Consortium) followed children aged 2–24 months with new-onset IS at 23 US centers (2012–2018), treated with ACTH, oral steroids or vigabatrin. Sustained response = last clinical spasms on or before treatment day 14, no hypsarrhythmia on EEG 2–4 weeks after treatment, and remission persisting to day 30. Infants without pretreatment hypsarrhythmia were more likely to respond early (HR 2.23, 95% CI 1.39–3.57).

  • Mytinger JR, Albert DVF, Twanow JD, et al. Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline. Pediatr Neurol. 2020;104:23-29. PMID 31911027 · DOI 10.1016/j.pediatrneurol.2019.11.016 PubMedDOI

    115 patients. Initial and 3-month remission: ACTH 66%/79%, prednisolone 53%/83%, vigabatrin 19%/40%. Here "compliance" means clinician guideline adherence, not caregiver adherence.

  • Chiron C, Dumas C, Jambaqué I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26(2):389-395. PMID 9095401 · DOI 10.1016/s0920-1211(96)01006-601006-6) PubMedDOI

    n=22. Spasm-free: vigabatrin (150 mg/kg/day) 11/11 vs hydrocortisone 5/11 (p<0.01). Mean time to cessation 3.5 vs 13 days. All 7 crossed over to vigabatrin were controlled.

  • Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14(2):71-74. PMID 10073425 · DOI 10.1177/088307389901400201 PubMedDOI

    Complete cessation in 73/77 (95%) with TSC vs 170/313 (54%) without.

  • Prezioso G, Chiarelli F, Matricardi S, et al. Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review. Expert Rev Neurother. 2023;23(7):661-671. PMID 37243682 · DOI 10.1080/14737175.2023.2216385 PubMedDOI

    17 studies. Overall response 67% (231/343). Spasm-free rate in RCTs 88% (29/33). Evidence is low level and heterogeneous.

  • Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50-66. PMID 34399110 · DOI 10.1016/j.pediatrneurol.2021.07.011 PubMedDOI

    2018 consensus update. Abstract: increased emphasis on early EEG screening for epileptiform abnormalities. (Full text was not accessible to us, so the vigabatrin-specific recommendation wording is unverified. Pull the exact sentence before quoting.)

  • Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304-314. PMID 33180985 · DOI 10.1002/ana.25956 · NCT02098759 PubMedDOI

    94 infants. Time to first seizure was longer with preventive than conventional vigabatrin: 364 vs 124 days in the RCT, 426 vs 106 days in the open-label trial. At 24 months, preventive treatment lowered the risk of clinical seizures (OR 0.21), DRE (OR 0.23) and IS (OR 0, p<0.001).

  • Bebin EM, Peters JM, Porter BE, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2024;95(1):15-26 (Epub 2023). PMID 37638552 · DOI 10.1002/ana.26778 · NCT02849457 PubMedDOI

    56 randomized (29 vigabatrin, 27 placebo). Bayley-III cognition at 24 months was similar. No difference in epilepsy incidence or DRE. IS incidence was lower and later with vigabatrin. Design and primary endpoint: phase IIb multicenter randomized double-blind placebo-controlled trial of vigabatrin at first epileptiform EEG vs vigabatrin at seizure onset. "Primary outcome was Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) cognitive assessment score at 24 months." Secondary: prevalence of DRE, other developmental outcomes, safety. 19/27 placebo infants moved to open-label vigabatrin (median 44 days after randomization).

  • Dean C, Mosier M, Penry K. Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia. 1999;40(1):74-82. PMID 9924905 · DOI 10.1111/j.1528-1157.1999.tb01991.x PubMedDOI

    n=174. ≥50% responders: placebo 7%; 1 g 24%; 3 g 51%; 6 g 54%. 6 g had more dropouts.

  • Bresnahan R, Gianatsi M, Maguire MJ, et al. Vigabatrin add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2020;7(7):CD007302. PMID 32730657 · DOI 10.1002/14651858.CD007302.pub3 PubMedDOI

    11 trials, 756 participants aged 10–64. ≥50% response RR 2.60 (95% CI 1.87–3.63), low certainty. Withdrawal RR 2.86. More dizziness (RR 1.74), fatigue (1.65), drowsiness (1.70) and depression (3.28). Results "should not be extrapolated to children under 10."

  • Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet. 1999;354(9172):13-19. PMID 10406359 · DOI 10.1016/s0140-6736(98)10531-710531-7) PubMedDOI

    n=459. Vigabatrin was less effective (time to first seizure p=0.0001) but better tolerated. Weight gain 11% vs 5%; psychiatric symptoms 25% vs 15%. Not recommended first-line. Design (abstract): Vigabatrin European Monotherapy Study Group; 44 European centres; newly diagnosed, previously untreated partial seizures; randomized double-blind to carbamazepine 600 mg daily (n=230) or vigabatrin 2 g daily (n=229), doses then adjusted by the clinician. Primary outcome: time to withdrawal for lack of efficacy or adverse events, which "did not differ between groups (p=0.318)". Vigabatrin had fewer withdrawals. Rash 3% vigabatrin vs 10% carbamazepine. "All efficacy outcomes favoured carbamazepine and failed to show equivalence"; time to 6-month remission not significantly different (p=0.058); time to first seizure after the first 6 weeks favoured carbamazepine (p=0.0001). Interpretation: "Vigabatrin seems less effective but better tolerated than carbamazepine"; it "cannot therefore be recommended as a first-line drug for monotherapy in this group of patients." ---

Safety

  • Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51(12):2423-2431. PMID 21070215 · DOI 10.1111/j.1528-1167.2010.02772.x PubMedDOI

    32 studies; 1,678 exposed and 406 controls. Field loss in 44% exposed vs 7% controls. Pooled: adults 52% (95% CI 46–59), children 34% (25–42). RR 4.0 (2.9–5.5). Risk rose with cumulative dose and age.

  • Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015;57(1):60-67. PMID 25145415 · DOI 10.1111/dmcn.12573 PubMedDOI

    School-age follow-up: visual field defects (VFDs) in 11/32 (34%). By duration: <1 y 9%, 12–24 mo 30%, >2 y 63%. TSC 6/10.

  • Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50(2):206-216. PMID 19215279 · DOI 10.1111/j.1528-1167.2008.01961.x PubMedDOI

    16 children treated in infancy (mean 21 months). Only 1 (6%) had mild loss. Risk may be lower with exposure in infancy.

  • Schwarz MD, Li M, Tsao J, et al. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Epilepsy Behav. 2016;57(Pt A):29-33. PMID 26921595 · DOI 10.1016/j.yebeh.2016.01.012 PubMedDOI

    143 treated. No clinically apparent vigabatrin-attributable vision loss (upper 95% bound 3.2%). Median exposure 8.6 months; median peak dose 141.5 mg/kg/day. Visual loss from any cause was 31% with vigabatrin vs 32% without.

  • Wild JM, Fone DL, Aljarudi S, et al. Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach. CNS Drugs. 2013;27(10):841-849. PMID 23990316 · DOI 10.1007/s40263-013-0100-z PubMedDOI

    147 adults with rCPS, median exposure 7.9 years. 59% had vigabatrin-associated visual field loss (VAVFL). Modelled frequency plateaued at about 76% after about 6 years or about 79% after 5 kg cumulative dose.

  • Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008;49(1):108-116. PMID 18184224 · DOI 10.1111/j.1528-1167.2007.01249.x PubMedDOI

    n=31 adults. Maximum daily dose, not cumulative dose or duration, was the only significant predictor of defect severity (p=0.012–0.020). (Indirect argument that unintended overdoses matter; speculative, do not overstate.)

  • Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111(10):1935-1942. PMID 15465561 · DOI 10.1016/j.ophtha.2004.03.036 PubMedDOI

    138 mostly infants with electroretinogram (ERG) every 6 months. 3 had definite peripheral retinal nerve-fiber-layer atrophy with "inverse" nasal optic atrophy.

  • Durbin S, Mirabella G, Buncic JR, et al. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest Ophthalmol Vis Sci. 2009;50(8):4011-4016. PMID 19279311 · DOI 10.1167/iovs.08-3237 PubMedDOI

    42 children with IS. Grating acuity (sweep VEP) was reduced in those with ERG-defined retinal toxicity.

  • Sergott RC, Westall CA. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011;(192):48-56. PMID 22061180 · DOI 10.1111/j.1600-0404.2011.01600.x PubMedDOI

    REMS designed around baseline exam within 4 weeks plus ongoing monitoring. Reviews perimetry, ERG and other methods for adults and infants.

  • Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011;(192):57-71. PMID 22061181 · DOI 10.1111/j.1600-0404.2011.01601.x PubMedDOI

    Bilateral field constriction also occurs, less often, in vigabatrin-naïve patients with epilepsy. Reviews the taurine-deficiency hypothesis.

  • Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184-194. PMID 18783433 · DOI 10.1111/j.1528-1167.2008.01728.x PubMedDOI

    New, reversible T2/DWI changes in 7/22 (32%) on vigabatrin, all treated for IS. Affected patients were younger (median 11 months) and on higher doses (170 vs 87 mg/kg/day). None of 56 unexposed IS patients had them.

  • Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50(2):195-205. PMID 19054414 · DOI 10.1111/j.1528-1167.2008.01896.x PubMedDOI

    205 infants with IS: MRI abnormalities in 22% with vigabatrin vs 4% without (p<0.001). Resolved in 6/9 with follow-up. No excess in children or adults with rCPS. (Source of the label's 22% vs 4%.)

  • Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010;51(7):1297-1304. PMID 20384718 · DOI 10.1111/j.1528-1167.2010.02564.x PubMedDOI

    25/81 (30.9%) had abnormal signal on vigabatrin ≥120 mg/kg/day, reversible on withdrawal. Higher risk at ≤12 months of age.

  • Hussain SA, Tsao J, Li M, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017;58(4):674-682. PMID 28230253 · DOI 10.1111/epi.13712 PubMedDOI

    Asymptomatic vigabatrin-associated MRI changes (VABAM) were linked to peak dose (p=0.0028), not cumulative dose; 6/40 asymptomatic scans. Symptomatic VABAM in 4/104, possibly linked to concurrent hormones (p=0.039). Caution above 175 mg/kg/day. (Peak-dose dependence is one reason to avoid accidental overdoses.) Design: retrospective single-center cohort (UCLA): 507 brain MRIs in 257 children with IS, reports reviewed blind to vigabatrin exposure; 143 vigabatrin-treated, detailed exposure data for 104.

  • Sathe R, Shrestha G, Terango A, et al. Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms. Epilepsia Open. 2025;10(1):314-320. PMID 39570186 · DOI 10.1002/epi4.13099 PubMedDOI

    VABAM in 17/108 (11 symptomatic). Symptomatic VABAM was linked to concurrent hormones (p=0.001) and not to peak dose. (Partly conflicts with Hussain 2017 on dose dependence.) Design: retrospective single-center cohort (UCLA Mattel Children's Hospital); 108 vigabatrin-treated children with detailed exposure data. The authors state the study "does not establish a causal link."

  • Walker SD, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand Suppl. 2011;(192):72-82. PMID 22061182 · DOI 10.1111/j.1600-0404.2011.01602.x PubMedDOI

    Common in infants: sedation, somnolence, irritability. In adults: drowsiness, dizziness, headache, fatigue. Depression and psychosis were more frequent than with placebo. Reviews the intramyelinic edema history. (See also label-vigafyde-2025 for somnolence, fatigue, weight gain and MRI figures, and lancet-1999-chadwick-vs-cbz for weight gain of 11% vs 5%.) ---

Mechanism and pharmacokinetics

  • Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):267-278. PMID 1395360 · DOI 10.2165/00003088-199223040-00003 PubMedDOI

    Racemic drug; the S(+) enantiomer is active, with no chiral inversion. Peak at 1–2 h, linear PK, no protein binding, Vd about 0.8 L/kg. Half-life 5.3–7.4 h (S+ 7.5 h). About 70% excreted renally. "The action of the drug long outlasts its presence in plasma." Reduce dose in renal impairment.

  • Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):19S-22S. PMID 2667604 · DOI 10.1111/j.1365-2125.1989.tb03456.x PubMedDOI

    Half-life 5–7 h. About 65% excreted unchanged in urine within 24 h. Dose-related rises in CSF GABA, consistent with GABA-transaminase (GABA-T) inhibition.

  • Gidal BE, Privitera MD, Sheth RD, et al. Vigabatrin: a novel therapy for seizure disorders. Ann Pharmacother. 1999;33(12):1277-1286. PMID 10630829 · DOI 10.1345/aph.18376 PubMedDOI

    Selective, irreversible GABA-T inhibitor. No clinically significant interactions and no need for level monitoring. Abstract: "Vigabatrin is a selective and irreversible inhibitor of gamma-aminobutyric acid transaminase." (For the GABA mechanism in label wording, see label-sabril-tablet-2021 §12.1: the effect is "believed to be" due to GABA-T inhibition, which "results in increased levels of GABA in the central nervous system.")

  • Nielsen JC, Kowalski KG, Karim A, et al. Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. Clin Pharmacokinet. 2014;53(11):1019-1031. PMID 25172554 · DOI 10.1007/s40262-014-0172-z PubMedDOI

    349 adults and 119 pediatric patients. Clearance rises with creatinine clearance. Absorption is slower in younger patients. In infants with IS, inter-occasion variability in relative bioavailability was 26.9%.

  • Jacqz-Aigrain E, Guillonneau M, Rey E, et al. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. Br J Clin Pharmacol. 1997;44(2):183-185. PMID 9278207 · DOI 10.1046/j.1365-2125.1997.00636.x PubMedDOI

    Case of TSC with renal failure and agitation on 3 g/day. Stereoselective accumulation of R(−). Hemodialysis clearance was about 5 L/h for both enantiomers. (Label PK, from label-sabril-tablet-2021 and label-vigafyde-2025: essentially complete absorption; infant Tmax about 2.5 h; infant t½ 5.7 h; infant CL 2.4 L/h; food lowers Cmax 33% with unchanged AUC; induces CYP2C9; lowers phenytoin 16–20%.) ---

Guidelines and consensus

  • Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974-1980. PMID 22689735 · DOI 10.1212/WNL.0b013e318259e2cf PubMedDOI

    PubMed now marks this guideline "[RETIRED]." Cite it as historical. Findings: ACTH more effective than vigabatrin short-term (excluding TSC); ACTH or vigabatrin "may be useful", with ACTH preferred; hormones preferred for cryptogenic IS for development; shorter lag to treatment possibly improves outcomes.

  • Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51(10):2175-2189. PMID 20608959 · DOI 10.1111/j.1528-1167.2010.02657.x PubMedDOI

    Consensus: early recognition, short-duration first-line therapy, timely EEG to judge response, prompt treatment changes.

  • Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56(8):1185-1197. PMID 26122601 · DOI 10.1111/epi.13057 PubMedDOI

    ACTH preferred for short-term spasm control (level B), oral steroids probably effective (level C), and shorter time to treatment may improve outcome (level C).

  • Erdemir G, Rao CK, Pino AF, et al. Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches. Epilepsia. 2026;67(9):4600-4617. PMID 42274306 · DOI 10.1002/epi.70329 PubMedDOI

    28 guidelines (16 published, 12 unpublished). Vigabatrin was universally recommended as first-line for TSC-associated IESS. Recent guidelines (2016–2024) increasingly endorse prednisolone and vigabatrin; combination therapy appears in about 25% after 2017. Response is usually assessed at about 14 days.

  • Freedman D, Babatunde I, Morgan RL, et al. American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy. Epilepsy Curr. 2026;26(3):174-202. PMID 41969626 · DOI 10.1177/15357597261433266 PubMedDOI

    Covers epilepsy from 1 to <36 months. Explicitly excludes West syndrome and IS ("existing treatment guidance is already available"). Useful only to show there is no newer US IS-specific guideline in this document.

  • Treadwell JR, Kessler SK, Wu M, et al. Pharmacologic and Dietary Treatments for Epilepsies in Children Aged 1-36 Months: A Systematic Review. Neurology. 2023;100(1):e16-e27. PMID 36270899 · DOI 10.1212/WNL.0000000000201026 PubMedDOI

    The evidence base for the AES guideline (excludes IS). Vigabatrin data were insufficient for conclusions in non-IS infant epilepsy.

  • Ramantani G, Bölsterli BK, Alber M, et al. Treatment of Infantile Spasm Syndrome: Update from the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society of Neuropediatrics. Neuropediatrics. 2022;53(6):389-401. PMID 35882373 · DOI 10.1055/a-1909-2977 PubMedDOI

    (Identity verified via esummary only; abstract not reviewed. Read before citing specifics.) ---

Emergency and support lines

  • 988 Suicide & Crisis Lifeline. SAMHSA, · Lifeline site Source

    SAMHSA page: "In Crisis? Call or Text 988"; "988 offers 24/7 judgment-free support for mental health, substance use, and more." 988lifeline.org: "Call, text, or chat with a 988 Lifeline counselor for help during difficult moments anytime, day or night." "The 988 Lifeline is available 24/7/365." "Your conversations are free and confidential." Get-help page: free services in Spanish 24/7; Veterans Crisis Line by calling 988 and pressing 1. Relevance: the AED class suicidal-behavior warning in the vigabatrin labels (label-sabril-tablet-2021 §5.5, label-vigafyde-2025 §5.11).

  • Poison Help line, 1-800-222-1222. MedlinePlus (National Library of Medicine), Poisoning: · HRSA Poison Help: Source

    MedlinePlus: "If you suspect someone has been poisoned, call your local poison control center at 1-800-222-1222 right away." (poisonhelp.hrsa.gov returned HTTP 403 to automated fetches, so HRSA's own page text is not verified here; the number is verified from MedlinePlus.) ---

Brand products: labels and approvals

  • Drugs@FDA (openFDA API): ANDA 214749, vigabatrin tablet 500 mg, sponsor Upsher-Smith Labs; original approval 2023-06-29; marketing status Prescription; TE code AB. openFDA brand name for this application: VIGADRONE (Upsher-Smith Laboratories, LLC; NDC 0245-6001). Source

    The same openFDA brand-name search returns ANDA 210196 (VIGADRONE for solution, 500 mg/packet, TE code AA, original approval 2018-06-21). So "Vigadrone" covers both a powder for oral solution and a tablet. Sabril in openFDA: NDA 020427 SABRIL tablet (TE code AB) and NDA 022006 SABRIL for solution (TE code AA), sponsor Lundbeck Pharms LLC, both original approval 2009-08-21.

  • VIGADRONE (vigabatrin) tablets prescribing information, Upsher-Smith Laboratories, LLC (Medication Guide revised 3/2023). ANDA 214749. Source

    Indications (§1): "Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; VIGADRONE is not indicated as a first line agent" and "Infantile Spasms – monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss." How supplied (§16.1): 500 mg white to off-white, oval, film-coated tablets, debossed "ZNV" on one side and scored on the other; bottles of 100. Store at 20 to 25 °C. Boxed warning: "WARNING: PERMANENT VISION LOSS"; available only through the Vigabatrin REMS Program (www.vigabatrinREMS.com, 1-866-244-8175).

Manufacturer support programs (existence and contact only)

  • Lundbeck. Sabril (vigabatrin) official US site and Sabril Prescription Form. · Source

    Site: "Branded Sabril (vigabatrin) is still available. Prescribers can continue to submit the Sabril Prescription Form through the SHARE Plus program." The optional form is faxed to SHAREPlus at 1-877-742-1002; alternatively a prescription can be sent "directly to a certified pharmacy found on the Vigabatrin REMS website." For brand Sabril, the prescriber indicates "Dispense as written (DAW)" or follows state rules for brand vs generic. Site: "The US Food and Drug Administration (FDA) has approved a single shared system Risk Evaluation and Mitigation Strategy (REMS) for all vigabatrin products, called the Vigabatrin REMS Program." (vigadrone.com carries the same sentence.) Form: SHAREPlus is described as "the patient support program", which uses the patient's information to "establish my benefit eligibility", communicate with providers and health plans about "benefit and coverage status", and "provide support services". The form also lets the office "perform a preliminary verification of the patient's insurance coverage for SABRIL" and "provide reimbursement support". Form: a one-time "Starter Rx" of up to a 30-day supply "is only available to new, eligible, commercially insured patients, ages 1 month to 2 years, who have been prescribed Sabril", while benefits investigation is ongoing. "All SHAREPlus terms and conditions apply."

  • Upsher-Smith. VIGADRONE Savings and Support. Source

    "Upsher-Smith's Promise of Support Program offers a spectrum of patient assistance from enrollment in the Vigabatrin REMS Program and completion of the prescription form by the prescriber, to arrival of the first shipment of VIGADRONE." Step 2: the program determines whether the patient is covered, not covered or uninsured, "Eligible for the co-pay assistance program", or needs a prior authorization; "While this is being done, a VIGADRONE starter/bridge supply is sent to the patient." "Prior authorization support can be provided only for indicated disease states." Step 3: the prescription "ships to the patient from our specialty pharmacy partner." Contact: phone 1-866-923-1954 (Monday to Friday, 8am to 8pm EST). Home page ( Vigadrone is "available as 500 mg powder for oral solution and 500 mg tablets."

  • Upsher-Smith. VIGAFYDE caregiver site, "Savings and the Promise of Support Program". Source

    The page lists, for eligible patients: copay help, a Patient Assistance Program for the uninsured or underinsured, help with "prior authorizations and appeals", a "Quick Start Program" ("Your baby will be able to start treatment while insurance approval is in progress"), specialty pharmacy pharmacist access "day or night", refill reminders and home delivery. Footnote: "Restrictions and limitations apply." The VIGAFYDE caregiver home page ( gives 1-888-650-3789 as a general contact number. It is not labeled as the program's line. (Dollar amounts on the page are not used: owner ruling, no prices.) ---

Medicare Part D coverage

  • Medicare.gov. What do drug plans cover? Source

    "A plan's list of covered drugs is called a 'formulary,' and each plan has its own formulary."

  • Medicare.gov. How do drug plans work? Source

    "To lower costs, many plans place drugs into different 'tiers' or levels on their drug lists." "Each plan can divide its tiers in different ways." "Generally, a drug in a lower tier will cost you less than a drug in a higher tier." Tier 1 is "most generic prescription drugs"; the specialty tier is for "very high-cost prescription drugs". "A Medicare drug plan can make changes to its drug list during the year under guidelines set by Medicare." "Your plan must notify you of any changes to their drug list that affect drugs you're taking."

  • Medicare.gov. Drug plan rules. Source

    Prior authorization: approval "that you and/or your prescriber must get from a plan for certain drugs before your plan will cover them." Step therapy: "a type of prior authorization that requires you first to try a certain, less expensive drug" before moving to a more expensive one. Quantity limits: "Plans may limit the amount of drugs they cover over a certain time period, for safety and cost reasons." Exceptions: "You or your prescriber can contact your plan to ask for an exception"; the prescriber must give a supporting statement that the drug is medically necessary. ---

Infantile spasms: definition and terminology

  • International League Against Epilepsy. Infantile epileptic spasms syndrome: overview. EpilepsyDiagnosis.org, Source

    Site is owned by the ILAE. "Infantile epileptic spasms syndrome is characterized by the onset of epileptic spasms in the infant (age 1-24 months)." Onset "between 1-24 months of age (peak 3-12 months)." IESS is a developmental and epileptic encephalopathy. West syndrome is one form, with a triad of "epileptic spasms, hypsarrhythmia on EEG and developmental plateauing or regression." "Developmental slowing or regression may be seen at onset of epileptic spasms." "Occasionally development may be normal and developmental trajectory continues as expected." Causes listed: structural brain abnormalities (developmental and acquired), chromosomal disorders, gene abnormalities and metabolic causes. Examples named: tuberous sclerosis, Down syndrome, ARX, CDKL5, SPTAN1, STXBP1.

  • International League Against Epilepsy. Epileptic spasms: overview. EpilepsyDiagnosis.org, Source

    An epileptic spasm is "a sudden flexion, extension or mixed flexion-extension of proximal and truncal muscles" "lasting 1-2 seconds" (longer than a myoclonic jerk, shorter than a tonic seizure, which lasts 3 seconds to minutes). "Spasms typically occur in a series, usually on wakening." If a single event, other seizure types should be considered. "Subtle forms may occur with only chin movement, grimacing, or head nodding." Spasms may be symmetric, asymmetric or one-sided.

  • International League Against Epilepsy. Infantile epileptic spasms syndrome: EEG. EpilepsyDiagnosis.org, Source

    Hypsarrhythmia: an interictal EEG that is "highly disorganized with high voltage irregular slow waves intermixed with multifocal spikes and polyspikes." Early on the EEG can look normal while awake, with abnormality that "may only be seen in sleep or on wakening"; "EEG abnormality is enhanced in drowsiness, in sleep and on wakening." "Some patients may have focal or multifocal discharges without hypsarrhythmia."

  • International League Against Epilepsy. Epilepsy imitators, and IESS differential diagnoses. EpilepsyDiagnosis.org, · Source

    IESS differential diagnoses listed by the ILAE include benign myoclonus of infancy and shuddering attacks, and non-epileptic head drops (and, among epilepsies, myoclonic epilepsy in infancy and late-onset spasms after 24 months). Benign neonatal sleep myoclonus: brief flurries of jerks; "The myoclonus only occurs in sleep." "Waking the child abolishes the movements." Benign myoclonus of infancy and shuddering attacks: onset typically from 4 months; a brief jerk or a shudder of head and trunk lasting a few seconds; occur while awake, often during feeding or in a high chair or car seat; "The events do not cause the child any distress." Sandifer syndrome (gastro-oesophageal reflux): "arching of the back, dystonic posturing of the limbs and turning/tilting of the head"; "Events are often seen with or after feeding." Non-epileptic head drops: begin at 3 to 6 months and resolve by 12 months; "Infants develop normally."

  • National Library of Medicine. Clinical Table Search Service, ICD-10-CM: G40.82. Source

    ICD-10-CM codes under G40.82 are titled "Epileptic spasms": G40.821 not intractable, with status epilepticus; G40.822 not intractable, without status epilepticus; G40.823 intractable, with status epilepticus; G40.824 intractable, without status epilepticus.

Infantile spasms: how common, causes and outcome

  • Barbour K, Tian N, Yozawitz EG, et al. Population-based study of rare epilepsy incidence in a US urban population. Epilepsia. 2024;65(8):2341-2353. PMID 38795333 · DOI 10.1111/epi.18029 PubMedDOI

    New York City health records, 2010–2014. Infantile epileptic spasms syndrome was the most common of 28 rare epilepsies, at 1 in 2,920 live births, within the published range.

  • Howell KB, Freeman JL, Mackay MT, et al. The severe epilepsy syndromes of infancy: A population-based study. Epilepsia. 2021;62(2):358-370. PMID 33475165 · DOI 10.1111/epi.16810 PubMedDOI

    Population-based study, Victoria, Australia, severe epilepsies with onset before 18 months. West syndrome and "WS-like" epilepsy (spasms without full hypsarrhythmia) were the most common syndromes: combined incidence 32.7 per 100,000 live births per year. Structural causes in 39% of West syndrome. Of 64 infants with West syndrome, WS-like or unifocal epilepsy, 19 (30%) had severe-profound delay at age 2 and 2 (3%) had died.

  • Widjaja E, Go C, McCoy B, Snead OC. Neurodevelopmental outcome of infantile spasms: A systematic review and meta-analysis. Epilepsy Res. 2015;109:155-162. PMID 25524855 · DOI 10.1016/j.eplepsyres.2014.11.012 PubMedDOI

    55 studies, 2,967 patients. Pooled good neurodevelopmental outcome 23.6% (95% CI 19.3–28.6%); no change after the first treatment guideline in 2004. Good outcome 54.3% with no known cause (cryptogenic) vs 12.5% with a known cause (symptomatic). Lead time to treatment under 4 weeks vs over 4 weeks: risk ratio 1.519 (95% CI 1.064–2.169) for good outcome (8 studies). Outcome methods varied widely.

  • Riikonen R. Long-term outcome of West syndrome: a study of adults with a history of infantile spasms. Epilepsia. 1996;37(4):367-372. PMID 8603642 · DOI 10.1111/j.1528-1157.1996.tb00573.x PubMedDOI

    214 Finnish children born 1960–1976, followed 20–35 years. Mortality 31% (67/214), deaths between 3 months and 30 years of age. 36 survivors (24%) had normal or only slightly impaired intelligence; some went on to academic jobs, partners and healthy children.

  • Harini C, Nagarajan E, Bergin AM, et al. Mortality in infantile spasms: A hospital-based study. Epilepsia. 2020;61(4):702-713. PMID 32133641 · DOI 10.1111/epi.16468 PubMedDOI

    150 patients born 2000–2011 at one US center, median follow-up 12 years. 25 (17%) died, 13 before age 5. In multivariate analysis, death was predicted by persisting epileptic spasms (OR 4.30) and significant respiratory comorbidity (OR 12.75). Most deaths before age 5 were from respiratory failure.

Infantile spasms: recognition, delay and video

  • Hussain SA, Lay J, Cheng E, et al. Recognition of Infantile Spasms Is Often Delayed: The ASSIST Study. J Pediatr. 2017;190:215-221.e1. PMID 29144248 · DOI 10.1016/j.jpeds.2017.08.009 PubMedDOI

    Survey of parents of 100 children with infantile spasms. Median time from spasm onset to a provider who recognized spasms and prescribed first-line treatment: 24.5 days. Only 29% were seen by such a provider within 1 week. Parents' suspicions that "something is wrong" were often discounted, and parents frequently reported that pediatricians and neurologists were unfamiliar with infantile spasms.

  • Rao CK, Nordli DR 3rd, Cousin JJ, et al. The Effect of Smartphone Video on Lead Time to Diagnosis of Infantile Spasms. J Pediatr. 2023;258:113387. PMID 36931494 · DOI 10.1016/j.jpeds.2023.02.035 PubMedDOI

    Retrospective cohort, 80 infants at 2 US centers. With a smartphone video, infants presented a median of 9 days earlier, had their first EEG 16 days earlier, and were diagnosed and treated 17 days earlier. The video group had a 25% greater response to first treatment; the long-term spasm-freedom difference lost significance after adjustment. Authors: pediatricians should recommend caregivers obtain smartphone video of concerning events.

  • Shrock CL, Savage MC, Sham L, et al. Smartphone videos for infantile epileptic spasms triaging and assessment (VISTA study): Impact of education and standardized clinical history on diagnostic accuracy. Epilepsia Open. 2026;11(4):1301-1313. PMID 42283429 · DOI 10.1002/epi4.70292 PubMedDOI

    180 clinicians viewed smartphone videos of EEG-confirmed spasms and non-epileptic mimics. Accuracy 64% at first viewing, 72% after brief training plus clinical history; sensitivity 0.85. Conclusion: smartphone videos can help triage and identify spasms early and reduce diagnostic delay.

  • MedlinePlus Medical Encyclopedia (National Library of Medicine). Moro reflex. Source

    "The Moro reflex is one of many reflexes that are seen at birth." It is triggered by a sudden change in head position (the head is "allowed to fall backward for a moment"). The baby looks startled, the arms spread outward with palms up and thumbs bent, and the baby may cry for a minute. "It normally goes away after 3 or 4 months." # Citation base: West syndrome, hypsarrhythmia and infantile spasms treatment (verified) Every PubMed entry below was checked against PubMed E-utilities (efetch for title, authors, journal, year, DOI and abstract). The Pavone review was read in PMC full text. The ILAE syndrome page was read live at epilepsydiagnosis.org. The Acthar Gel facts come from the current DailyMed SPL XML. Nothing in this file was taken from memory. Anything we could not verify is listed under "Not verified / dropped". ---

West syndrome and IESS: definitions, causes and outcome

  • ILAE. Infantile epileptic spasms syndrome (IESS) overview. EpilepsyDiagnosis.org (International League Against Epilepsy diagnostic manual). Source

    "Infantile epileptic spasms syndrome is characterized by the onset of epileptic spasms in the infant (age 1-24 months)." "This syndrome includes West syndrome, where patients have a triad of epileptic spasms, hypsarrhythmia on EEG and developmental plateauing or regression." Onset of epileptic spasms between 1 and 24 months of age, peak 3 to 12 months. Both sexes are affected, with a male predominance. "Developmental slowing or regression may be seen at onset of epileptic spasms"; occasionally development may be normal and continue as expected. Causes listed (no percentages): structural brain abnormalities (developmental and acquired), chromosomal disorders, gene abnormalities, metabolic causes.

  • Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1349-1397. PMID 35503712 · DOI 10.1111/epi.17239 PubMedDOI

    (Abstract only; full text is subscription.) ILAE classification of epilepsy syndromes with seizure onset up to 2 years of age. Syndromes are separated into self-limited syndromes (likely spontaneous remission) and developmental and epileptic encephalopathies, where developmental impairment relates both to the underlying cause and to the epileptic activity. Tables give mandatory features, alerts and exclusions; guidance is given for resource-limited regions where EEG, MRI or genetic testing may not be available.

  • Pavone P, Polizzi A, Marino SD, et al. West syndrome: a comprehensive review. Neurol Sci. 2020;41(12):3547-3562. PMID 32827285 · DOI 10.1007/s10072-020-04600-5 · PMC7655587 PubMedDOI

    Abstract: first clinical description by William James West (1793-1848), on his own son, in 1841. The classical triad is (1) infantile spasms, (2) hypsarrhythmia and (3) developmental arrest or regression. Spasms may present atypically (subtle spasms, modified hypsarrhythmia) and can begin outside infancy. (Full text) West syndrome is regarded as a subtype of infantile spasms syndrome and presents in about 90% of cases. Classic spasms are short, abrupt flexions of the trunk and neck with arm adduction, bilaterally symmetric, each lasting a few seconds, occurring on waking and in clusters. Hypsarrhythmia is described as a "chaotic mixture of very high amplitude slow waves" with spikes and waves varying in amplitude, shape, duration and site. "Atypical" or "modified hypsarrhythmia" includes asymmetric features, focal discharges and semi-periodic burst-suppression. (Full text) Narrative review, outcome section citing older cohorts: transition from infantile spasms to Lennox-Gastaut syndrome "is reported to occur in 18% of cases"; spasms tend to disappear by 3 to 4 years of age. In a 147-person cohort followed 20-35 years, seizures had remitted in about a third. ASD reported in 19.9% of people with infantile spasms in one meta-analysis. The review names the underlying cause as the main driver of prognosis. (Full text, re-checked in PMC7655587) "The spasms may appear in flexion, extension or in mixed patterns with episodes of cry or scream, which may precede or follow the spasm itself." (Full text, re-checked in PMC7655587) "The classical presentation of WS consists in short episodes of abrupt flexion of the trunk and neck and adduction of the arms"; the spasms are "bilaterally symmetric, each lasting few seconds and occurring at wakening and in clusters." (Full text, re-checked in PMC7655587, Clinical outcome) "In most patients, developmental delay, ranging from mild to severe degrees occurs prior to the onset of IS or, sometimes, may be concurrent or may follow the first ictal events. It must be noted, however, that it is not easy to recognize the delay at such early ages."

  • Hrachovy RA, Frost JD Jr. Infantile spasms. Handb Clin Neurol. 2013;111:611-618. PMID 23622208 · DOI 10.1016/B978-0-444-52891-9.00063-4 PubMedDOI

    Average age at onset is 6 months; average incidence about 0.31 per 1,000 live births. About one-quarter stop having spasms spontaneously within 1 year of onset. Three main spasm types: flexor, extensor and mixed. Spasms often come in clusters and on arousal from sleep, and are frequently confused with normal and abnormal infant behaviors. The interictal EEG typically shows hypsarrhythmia or a variant. The primary treatment objective is to improve the EEG and stop the spasms as soon as possible. Abstract (re-checked via PubMed efetch): "A variety of ictal EEG patterns may be seen, the most common of which is a generalized slow-wave transient followed by an attenuation of the background activity in all regions."

  • Osborne JP, Lux AL, Edwards SW, et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia. 2010;51(10):2168-2174. PMID 20726878 · DOI 10.1111/j.1528-1167.2010.02695.x PubMedDOI

    207 infants: 127 (61%) proven cause, 68 (33%) no identified cause, 12 (6%) not fully investigated. Causes were prenatal in 63, perinatal in 38, postnatal in 8. Most common: hypoxic-ischemic encephalopathy 10%, chromosomal 8%, malformations 8%, stroke 8%, tuberous sclerosis complex 7%, periventricular leukomalacia or hemorrhage 5%. The remaining 32 causes were each uncommon.

  • Sillanpää M, Riikonen R, Saarinen MM, Schmidt D. Long-term mortality of patients with West syndrome. Epilepsia Open. 2016;1(1-2):61-66. PMID 29588929 · DOI 10.1002/epi4.12008 · PMC5867832 PubMedDOI

    All children born 1960-1976 treated for West syndrome at three Helsinki hospitals, followed for five decades. 102 of 207 (49%) had died, at a mean age of 19 years. 25% had died by 17.2 years of follow-up and 50% by 48.6 years. Hazard of death was fivefold with a known (symptomatic) cause vs unknown (cryptogenic) cause; annual mortality 17.6 vs 3.7 per 1,000. Pneumonia was the most frequent cause of death (46%); SUDEP was the most common epilepsy-related cause (10%). Limit: children born 1960-1976; care has changed since.

  • Iype M, Anish TS, Saradakutty G, et al. Long-term survival and factors associated with mortality among children with infantile epileptic spasms syndrome - A retrospective cohort study. Seizure. 2023;112:18-25. PMID 37729722 · DOI 10.1016/j.seizure.2023.09.005 PubMedDOI

    Single center (India), 160 children, 120 months follow-up: 19 (11.9%) died. Severe pneumonia was the cause in 10. Mortality was predicted by seizures other than spasms and an inborn error of metabolism as the cause. None of the children in the idiopathic group died. Authors call survival good compared with earlier studies.

  • Riikonen R. Infantile Spasms: Outcome in Clinical Studies. Pediatr Neurol. 2020;108:54-64. PMID 32305143 · DOI 10.1016/j.pediatrneurol.2020.01.015 PubMedDOI

    Review of mainly prospective studies. Underlying cause is the most important prognostic factor. In studies with follow-up up to 50 years, a favorable cognitive outcome was seen in about one quarter and complete seizure freedom in one third. Autism is relatively frequent and premature mortality is high throughout life. Hormonal treatment (ACTH or prednisolone) is the optimal monotherapy in most studies, except TSC, where vigabatrin appears superior. Modifiable prognostic factors: early recognition with prompt treatment, short duration of hypsarrhythmia, prompt treatment of relapses, early treatment of adverse effects.

  • Mytinger JR. Definitions and Diagnostic Criteria for Infantile Spasms and West Syndrome - Historical Perspectives and Practical Considerations. Semin Pediatr Neurol. 2021;38:100893. PMID 34183140 · DOI 10.1016/j.spen.2021.100893 PubMedDOI

    No formal consensus on diagnostic criteria for West syndrome. Infantile spasms is a seizure type; West syndrome is an epilepsy syndrome. Over-reliance on hypsarrhythmia is "particularly problematic" because many children with infantile spasms do not have the classic pattern and its determination has poor inter-rater reliability; strict definitions risk inappropriately withholding standard therapy from children who do not meet criteria for West syndrome.

  • Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia. 2004;45(11):1416-1428. PMID 15509243 · DOI 10.1111/j.0013-9580.2004.02404.x PubMedDOI

    31 participants from 15 countries approved the final statement. Primary clinical outcome (cessation of spasms): no witnessed spasms from within 14 days of starting treatment, lasting at least 28 consecutive days from the last witnessed spasm. Primary electroclinical outcome: cessation of spasms with resolution of hypsarrhythmia. West syndrome should be a defined subset of the syndrome of infantile spasms. Consensus was not reached on a definition of hypsarrhythmia.

Hypsarrhythmia: EEG pattern and reliability

  • Hrachovy RA, Frost JD Jr, Kellaway P. Hypsarrhythmia: variations on the theme. Epilepsia. 1984;25(3):317-325. PMID 6539199 · DOI 10.1111/j.1528-1157.1984.tb04195.x PubMedDOI

    Prolonged monitoring shows hypsarrhythmia is a highly variable and dynamic pattern. Variations (modified hypsarrhythmia): increased interhemispheric synchronization, asymmetrical hypsarrhythmia, a consistent focus of abnormal discharge, episodes of attenuation, and mainly high-voltage slow activity with little sharp-wave or spike activity. Marked changes occur in sleep, especially REM sleep, when the pattern is markedly reduced or disappears. Relative normalization can occur immediately on arousal and during clusters of spasms. What is seen depends on recording length, the infant's state and brain structure.

  • Hussain SA, Kwong G, Millichap JJ, et al. Hypsarrhythmia assessment exhibits poor interrater reliability: a threat to clinical trial validity. Epilepsia. 2015;56(1):77-81. PMID 25385396 · DOI 10.1111/epi.12861 PubMedDOI

    Hypsarrhythmia is "the classic interictal electroencephalographic pattern associated with infantile spasms", characterized by high voltage, disorganization and multifocal independent epileptiform discharges. Six blinded pediatric electroencephalographers from four centers rated 22 five-minute awake EEG samples. Agreement on normal vs abnormal was high (κ=0.89) but low for hypsarrhythmia (κ=0.40), modified hypsarrhythmia (κ=0.47), high voltage (κ=0.37) and disorganization (κ=0.22). Raters still reported high confidence.

  • Mytinger JR, Hussain SA, Islam MP, et al. Improving the inter-rater agreement of hypsarrhythmia using a simplified EEG grading scale for children with infantile spasms. Epilepsy Res. 2015;116:93-98. PMID 26280806 · DOI 10.1016/j.eplepsyres.2015.07.008 PubMedDOI

    BASED (Burden of Amplitudes and Epileptiform Discharges) score focuses on discharge burden and background slow-wave amplitude. 40 EEG clips (20 before, 20 after treatment) from 20 children, three blinded reviewers. Agreement on hypsarrhythmia: κ 0.87 with BASED vs 0.09 with traditional analysis; all three agreed in 37/40 (93%) vs 15/40 (38%) epochs.

  • Cramer TP, Johnsen B, Hansen VS, et al. Inter-rater reliability and clinical utility of the BASED score in infantile epileptic spasms syndrome. Epileptic Disord. 2026;28(4):1132-1140. PMID 42011098 · DOI 10.1002/epd2.70255 PubMedDOI

    Hypsarrhythmia's main characteristics (multifocal spikes, large-amplitude slow waves, chaoticity) lack clear definitions and inter-rater reliability is poor. Three Danish neurophysiologists rated before- and after-treatment EEGs of 20 patients. Agreement on an epileptic encephalopathy was better with BASED than traditional scoring (Gwet's AC1 0.88 vs 0.62); complete agreement 36/40 vs 28/40 EEGs.

Infantile spasms treatment: hormones and second treatment

  • Wanigasinghe J, Arambepola C, Sri Ranganathan S, et al. Randomized, Single-Blind, Parallel Clinical Trial on Efficacy of Oral Prednisolone Versus Intramuscular Corticotropin on Immediate and Continued Spasm Control in West Syndrome. Pediatr Neurol. 2015;53(3):193-199. PMID 26216500 · DOI 10.1016/j.pediatrneurol.2015.05.004 PubMedDOI

    Single center (Sri Lanka), 97 infants, 14 days of oral prednisolone 40-60 mg/day vs synthetic long-acting IM ACTH 40-60 IU every other day (UKISS protocol). Spasms stopped by day 14 in 28/48 (58.3%) on prednisolone vs 18/49 (36.7%) on ACTH (p=0.03). Electroclinical remission (spasms stopped plus resolution of hypsarrhythmia) 21 vs 9 (p=0.007). Mean days to cessation 3.85 vs 8.65.

  • Chellamuthu P, Sharma S, Jain P, et al. High dose (4 mg/kg/day) versus usual dose (2 mg/kg/day) oral prednisolone for treatment of infantile spasms: an open-label, randomized controlled trial. Epilepsy Res. 2014;108(8):1378-1384. PMID 25048310 · DOI 10.1016/j.eplepsyres.2014.06.019 PubMedDOI

    63 children (3 months to 2 years). Spasm cessation at day 14 (parent report): 51.6% on 4 mg/kg/day vs 25% on 2 mg/kg/day (p=0.03); number needed to treat 4. Adverse effects comparable.

  • Osborne JP, Edwards SW, Alber FD, et al. Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. Eur J Paediatr Neurol. 2023;42:110-116. PMID 36621063 · DOI 10.1016/j.ejpn.2022.12.007 PubMedDOI

    Individual data from UKISS and ICISS, hormone monotherapy only, 126 infants. Minimum treatment prednisolone 40 mg/day for two weeks or tetracosactide depot 0.5 mg IM on alternate days for two weeks, then a two-week prednisolone taper. Spasm-free days 13-14: tetracosactide 47/62 (76%) vs prednisolone 43/64 (67%), p=0.28. Days 14-42: 67% vs 56%, p=0.22. Development scores (VABS 78.0 vs 74.8) and ongoing epilepsy (33% vs 41%) not significantly different. Conclusion: either may be recommended.

  • Farias EH, Silva AMPD, Santos KDAD, et al. Corticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis. Arq Neuropsiquiatr. 2025;83(8):1-8. PMID 40886708 · DOI 10.1055/s-0045-1811173 · PMC12399325 PubMedDOI

    ACTH vs corticosteroids: no significant difference in spasm cessation at day 14 (OR 0.91), hypsarrhythmia resolution (OR 0.97), irritability, hypertension (RR 0.64) or infection (RR 0.69). ACTH was linked to more weight gain (RR 1.41, 95% CI 1.01-1.97). Significant heterogeneity between studies limits the analysis.

  • Grinspan ZM, Knupp KG, Patel AD, et al. Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort. Neurology. 2021;97(12):e1217-e1228. PMID 34266919 · DOI 10.1212/WNL.0000000000012511 · PMC8480478 PubMedDOI

    National Infantile Spasms Consortium, 23 US centers (2012-2018). Freedom from treatment failure at 60 days (no second treatment and no spasms after day 30): ACTH 46% (88/190), oral steroids 44% (42/95), vigabatrin 37% (32/87), nonstandard therapy 8% (4/51). Switching from oral steroids to ACTH was not estimated to change response. ACTH and oral steroids were superior to nonstandard therapy. Among children on vigabatrin, those with TSC responded more often (62% vs 29%). Class III evidence; vigabatrin comparisons underpowered.

  • Knupp KG, Leister E, Coryell J, et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia. 2016;57(11):1834-1842. PMID 27615012 · DOI 10.1111/epi.13557 · PMC5863234 PubMedDOI

    118 infants at 19 centers whose first treatment failed (no clinical remission or persisting hypsarrhythmia). Overall response to a second treatment 37% (44/118). Standard medicines with a different mechanism for first and second treatment (hormonal then vigabatrin, or the reverse) responded more often: 55% (27/49) vs 25% (17/69), p<0.001. First treatment within 4 weeks of onset: response to the second treatment 44% (36/82) vs 24% (8/34) when started later (p=0.040).

  • ACTHAR GEL (repository corticotropin injection) prescribing information and Medication Guide (current DailyMed SPL; Recent Major Changes dated 10/2026). Source

    Indication (§1.1): "monotherapy for the treatment of infantile spasms in infants and children under 2 years of age." Dosing (§2.2): intramuscular only for infantile spasms (vial, not the pre-filled injector). 150 U/m² per day as two IM injections of 75 U/m² for 2 weeks, then a gradual taper over 2 weeks "to avoid adrenal insufficiency". Common adverse reactions in infantile spasms (§6.1, ≥5% at the recommended twice-daily dose): increased risk of infections, convulsions, hypertension, irritability and pyrexia. Table (75 U/m² twice daily, n=122): infections 20%, hypertension 11%, Cushingoid 3%; at 150 U/m² once daily (n=37): infections 46%, hypertension 19%, Cushingoid 22%. Data from retrospective chart reviews and trials; numbers in controlled trials were too few for meaningful rates. Warnings: infections (and masked signs of infection), adrenal insufficiency after stopping, Cushing's syndrome, raised blood pressure, salt and water retention, low potassium. Effects on growth are "of particular concern" in children. Adrenal insufficiency symptoms in infants can be hard to identify (anorexia, fatigue, lethargy, weakness, weight loss, low blood pressure, abdominal pain). Other seizures (§6.1, §17): "some patients with infantile spasms progress to other forms of seizures (for example, Lennox-Gastaut Syndrome)", and spasms sometimes mask other seizures that become visible once spasms resolve. Clinical study (§14): responder = complete suppression of both clinical spasms and hypsarrhythmia on a full sleep-cycle video EEG 2 weeks after starting, read blind. 13/15 (86.7%) responded to Acthar vs 4/14 (28.6%) on prednisone 1 mg/kg twice daily (p<0.002). 7 of 8 prednisone non-responders then responded to Acthar. (Small trial; prednisone dose lower than the high-dose prednisolone regimens in later trials.)

Giving liquid medicine to babies and children at home

  • MedlinePlus (National Library of Medicine). Vigabatrin. Source

    "Talk to the doctor about what to do if your baby vomits, spits up, or only takes part of the dose of vigabatrin." Missed dose: take it when remembered unless it is almost time for the next one; "Do not take a double dose to make up for a missed one." "Talk to your doctor about what you should do if your baby misses a dose of vigabatrin." Powder: mix with cold or room-temperature water immediately before taking; "Do not mix the powder with any other liquid or food." "Do not use a household spoon to measure your dose." "Use the oral syringe that came with the medication." "Do not stop taking vigabatrin without talking to your doctor."

  • Nemours KidsHealth. Oral Medicines: How to Give Them to Your Child. The Nemours Foundation. Source

    Give the medicine with the device that comes with it or that the health care provider recommends. "Don't use a kitchen spoon to measure medicine." With a syringe, take off the small cap on the end and throw it away before giving the medicine. "Do not mix medicine in a baby bottle." If the baby doesn't finish the bottle, they won't get enough medicine. Call the health care provider if the child "spits out, vomits up, or won't take the medicine", if a dose is forgotten, or if you are not sure of the dose or device.

  • Great Ormond Street Hospital for Children NHS Foundation Trust. How to give your child liquid medicines. Source

    Make sure the child is sitting upright. Put the syringe tip inside the mouth "between the gums and the inside surface of their cheek." Push the plunger gently to give small amounts into the side of the mouth, letting the child swallow in between. Do not squirt the whole dose in one go (the child may choke). A drink afterwards helps wash it down. Some syringes are marked in mL and some in mg; check before each dose. Some medicines come in different strengths, so check the dose. Use the measuring device supplied; a household spoon will not give an accurate dose. Cleaning: wash in warm soapy water; some cleaning fluids remove the dose markings, which makes the syringe unsafe to use. Let parts dry naturally away from heat and sunlight.

  • Seattle Children's Hospital. Medicine - Refusal to Take (Schmitt Pediatric Guidelines). Source

    Position: sitting up, never lying down; swallowing cannot happen if the head is bent backward. "Do not squirt medicine into the back of the throat," because it can enter the windpipe and cause choking. You can aim for the pouch inside the cheek. "Forcing a struggling child to take any medicine can lead to vomiting or choking." If the child will not cooperate, two adults are often needed. Call if a child refuses a prescription medicine and good technique has not helped.

  • Institute for Safe Medication Practices (ISMP). Patient access to appropriately sized oral/enteral medication syringes is needed. ISMP Medication Safety Alert! Acute Care. 2026;31(7):1-4. Source

    2025 GEDSA/Oley Foundation survey of 412 patients and parents of children with feeding tubes (92% in the US). 97% gave medicines through the tube; 83% used ENFit connectors. Mismatch: 31% of people with doses under 6 mL used a 60 mL syringe, although only 11% had doses above 20 mL. 55% had difficulty getting syringes and 74% had difficulty getting bottle adapters. Syringes were reused an average of 32 times, though most are not FDA-approved for reuse; 19% used them until they failed, for example when the markings became unreadable. Pharmacy recommendations: dispense the syringe that most closely matches the prescribed volume; metric-only dosing devices (no teaspoons); mark the syringe where to measure the dose. Caregiver recommendations: learn how to read syringe markings and measure doses; use teach-back to confirm accurate measuring and giving. ---

Medicines through enteral feeding tubes

  • American Society for Parenteral and Enteral Nutrition (ASPEN). Medications via Enteral Feeding Tubes: A Clinician's Guide (practice tool). 2026. Source

    Practice tool, not an ASPEN guideline (its disclaimer says so). Aimed at clinicians; covers home patients and discharge teaching. "Do not mix medications together" (drug-drug interactions, precipitates that may clog tubes). "Do not add medications directly to tube feeding formulas." Prepare each medication individually, just before giving. Hold or stop tube feeds during medication delivery. Flush with water before and after each medication (clinician figure: at least 15 mL of purified water). With a GJ tube, determine whether the medicine goes through the G-port or the J-port. "Ensure proper form of medication for route and size of feeding tube." Do not crush modified-release or enteric-coated tablets; film-coated tablets can raise the risk of clogging. "Use ENFit syringes for medication delivery to feeding tubes." "Use low-dose tip ENFit syringes for lower dose medications where exact dosing is critical." Use an ENFit bottle cap or bottle adapter to draw liquid from a bottle. Teaching for home should include "matching the medication with the size of syringe to be used." Clean medication syringes if they are to be reused; otherwise discard. Cites an ISMP-published GEDSA survey: home patients use syringes much larger than the dose, raising the risk of dose error, and more than half had trouble getting smaller syringes.

  • NHS Specialist Pharmacy Service (SPS). Administering a medicine through an enteral feeding tube. Source

    "Prepare the medicines separately. Never mix medicines." Flush before the first medicine, between medicines, and after the last one (adult figures 30 mL / 10 mL / 30 mL); "Flushing volumes may need to be reduced for fluid restricted or paediatric patients." "Use EnFit® (ISO 80369-3) syringes for flushing and medicine administration." Using appropriate water reduces the risk of infection or tube blockage.

  • AHRQ Patient Safety Network (PSNet). Potential for medication overdose with ENFit low dose tip syringe: FDA Safety Communication (FDA MedWatch alert, October 2021). Source

    PSNet summary: the FDA communication highlights possible dose inaccuracy from the design of the low dose tip (LDT) syringe and gives cleaning methods and other actions for patients, families and clinicians to protect dose accuracy. (The FDA's own page returned 404 to automated fetches; only the PSNet summary is verified. Do not quote FDA details such as the "moat" steps from this entry.) ---

Seizure aggravation (absence, myoclonic)

  • Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000;22(2):75-80. PMID 10722956 · DOI 10.1016/s0387-7604(99)00113-800113-8) PubMedDOI

    Review. Idiopathic generalised epilepsies "are particularly prone to pharmacodynamic aggravation: typical absences are constantly increased by carbamazepine (CBZ), vigabatrin, tiagabine, gabapentin". In symptomatic generalised epilepsies, "myoclonias are generally aggravated by the same drugs that aggravated IGEs". Advises treating according to seizure type or epilepsy type.

  • Yang MT, Lee WT, Chu LW, et al. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev. 2003;25(1):51-56. PMID 12536034 · DOI 10.1016/s0387-7604(02)00120-100120-1) PubMedDOI

    Three patients with new (de novo) absence seizures after carbamazepine and vigabatrin; the seizures "subsides rapidly after discontinuing the use of the offending drugs." Drug-induced aggravation should be considered "whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment."

Chemistry and controlled-substance schedules

  • PubChem Compound Summary: vigabatrin, CID 5665. National Library of Medicine. Source

    Molecular formula C6H11NO2; molecular weight 129.16; IUPAC name 4-aminohex-5-enoic acid; SMILES C=CC(CCC(=O)O)N (no stereocenter specified, i.e. the racemate).

  • DEA Diversion Control Division. Controlled Substances: Alphabetical Order (the "Orange Book" list of substances scheduled under the Controlled Substances Act). Source

    Vigabatrin does not appear on the list (searched for "vigabatrin" and "Sabril"). Some other seizure medicines are listed in Schedule V, e.g. pregabalin (Lyrica), lacosamide (Vimpat) and cenobamate.

History: vision loss reports

  • Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180-181. PMID 9022432 · DOI 10.1136/bmj.314.7075.180 PubMedDOI

    Report (no abstract in PubMed) whose title describes severe, persistent visual field constriction associated with vigabatrin. Cite only for the fact that such a report was published in the BMJ in 1997. # Citation base: tuberous sclerosis and seizures in babies (verified) Sources for /tuberous-sclerosis and /seizures-in-babies. PubMed entries were checked against PubMed E-utilities (esummary for authors, journal, volume, pages and DOI; efetch for the abstract). Entries marked "(full text)" were read in the PMC full text fetched through E-utilities. MedlinePlus and CDC facts come from the live pages. The everolimus label facts come from the current DailyMed SPL XML. Nothing here was taken from memory. ---

Tuberous sclerosis complex: disease facts

  • Tuberous sclerosis complex. MedlinePlus Genetics (National Library of Medicine). Source

    "Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body." Tumors can occur in the brain, kidneys, heart, skin and other organs. Frequency: "affects 1 in 6,000 to 10,000 people." Causes: variants in TSC1 or TSC2, which make hamartin and tuberin. The proteins work together to regulate cell growth, division and size, and act as tumor suppressors. Tumors need a second change in the other copy of the gene during life. Inheritance: autosomal dominant. "In about one-third of cases, an affected person inherits an altered TSC1 or TSC2 gene from a parent who has the disorder. The remaining two-thirds of people with tuberous sclerosis complex are born with new variants." Mosaicism is described for rare cases with no identified variant. Features: cortical tubers; TSC-associated neuropsychiatric disorders (TAND), including hyperactivity, aggression, psychiatric conditions, intellectual disability and autism spectrum disorder; ADHD or seizures; kidney tumors that can cause severe problems with kidney function; cardiac rhabdomyoma; retinal tumors; LAM in some women (cough, shortness of breath, chest pain, lung collapse). "Virtually all affected people have skin abnormalities", including light-colored patches, raised thickened skin and growths under the nails. Facial angiofibromas "are also common beginning in childhood."

  • Tuberous sclerosis. MedlinePlus Medical Encyclopedia (National Library of Medicine). Source

    Two-thirds of cases are due to new gene changes; in most cases there is no family history. A parent with TSC has a 50% chance of passing it to each child. Skin: white patches with an "ash leaf or confetti appearance"; red patches on the face with many blood vessels (facial angiofibromas); raised patches with an orange-peel texture (shagreen spots), often on the back. Brain: autism spectrum disorders, developmental delays, intellectual disability, seizures. Other: pitted tooth enamel, growths around the nails, LAM (more common in women), cardiac rhabdomyoma, which "is common in children with tuberous sclerosis and can be seen on ultrasound before a baby is born." "Some people have normal intelligence and no seizures. Others have intellectual disabilities or difficult-to-control seizures." Tests: head CT or MRI, chest CT, echocardiogram, kidney ultrasound, ultraviolet light skin exam, DNA testing for TSC1 or TSC2. Regular kidney ultrasound checks are important. Treatment: "There is no known cure." "Some seizures are controlled with medicine (vigabatrin is first line for infantile spasms). Other children may need surgery." Facial angiofibromas may be removed by laser and tend to come back. Cardiac rhabdomyomas commonly disappear after puberty and usually need no surgery. Brain tumors can be treated with mTOR inhibitors (sirolimus, everolimus). Everolimus may be used for kidney tumors that do not need surgery right away. Contact a genetic specialist if a child is diagnosed with a heart rhabdomyoma; TSC is the leading cause of this tumor. (Live page, re-checked) Treatment: "Depending on the severity of the intellectual disability, the child may need special education." "Kidney tumors are treated with surgery, or by reducing the blood supply using special x-ray techniques." (Live page, re-checked) Outlook: "The tumors in this disease tend to be noncancerous (benign). However, some tumors (such as kidney or brain tumors) can become cancerous." (Live page, re-checked) Prevention: "Genetic counseling is recommended for couples who have a personal or family history of tuberous sclerosis and who want to have children."

  • Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243-254. PMID 24053982 · DOI 10.1016/j.pediatrneurol.2013.08.001 · PMC4080684 PubMedDOI

    (Full text) Genetic criterion: a TSC1 or TSC2 pathogenic variant in DNA from normal tissue is enough for a definite diagnosis. 10% to 25% of patients have no variant found by conventional testing, and a normal result does not exclude TSC. (Full text) 2012 clinical criteria, 11 major features: hypomelanotic macules (3 or more, at least 5 mm), angiofibromas (3 or more) or fibrous cephalic plaque, ungual fibromas (2 or more), shagreen patch, multiple retinal hamartomas, cortical dysplasias, subependymal nodules, SEGA, cardiac rhabdomyoma, LAM, angiomyolipomas (2 or more). Minor features: "confetti" skin lesions, dental enamel pits, intraoral fibromas, retinal achromic patch, multiple renal cysts, nonrenal hamartomas. "Definite diagnosis: Two major features or one major feature with ≥2 minor features. Possible diagnosis: Either one major feature or ≥2 minor features." LAM plus angiomyolipomas without other features does not meet criteria for a definite diagnosis. (Full text) Frequencies: hypomelanotic macules in about 90%, typically at birth or in infancy, and may be a presenting sign; facial angiofibromas in about 75%, onset typically between ages 2 and 5; ungual fibromas about 20% overall, up to 80% in older adults, usually from the second decade; shagreen patches commonly large plaques on the lower back with a bumpy or orange-peel surface. Nearly 100% have skin or dental findings. Cortical tubers in about 90%; subependymal nodules in 80%; SEGA in 5% to 15%, mostly arising in childhood or adolescence, and can cause hydrocephalus. (Full text) Cardiac rhabdomyomas are frequently seen in fetal life, often regress after birth, and are often the first noted sign. A prenatal cardiac rhabdomyoma carries a 75% to 80% risk of TSC. LAM typically presents with breathlessness on exertion and repeated collapsed lung in the third to fourth decade of life. Lung cysts consistent with LAM are seen in 30% to 40% of females with TSC, possibly up to 80% by age 40; symptomatic LAM in males is very rare. (Full text) Incidence 1 in 6,000 to 1 in 10,000 live births.

  • ICD-10-CM code Q85.1, Tuberous sclerosis. NLM Clinical Table Search Service, ICD-10-CM (National Library of Medicine). Source

    The NLM ICD-10-CM table returns code Q85.1 with the name "Tuberous sclerosis".

Epilepsy in tuberous sclerosis complex

  • Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236-1241. PMID 20041940 · DOI 10.1111/j.1528-1167.2009.02474.x PubMedDOI

    Chart review of 291 patients with TSC at one center. 85.2% had a history of seizures; 37.8% had infantile spasms; 63.2% had seizure onset in the first year of life; 54.1% developed multiple seizure types. 12.1% of adults without a seizure history developed epilepsy. Of those with epilepsy, 62.5% developed refractory epilepsy and 33.5% achieved remission. Infantile spasms were a risk factor for refractory epilepsy and Lennox-Gastaut syndrome. Seizure history, spasms, age at onset and refractory epilepsy correlated with poorer cognitive outcome; remission correlated with better outcome. TSC2 was a risk factor for spasms and epilepsy.

  • Nabbout R, Belousova E, Benedik MP, et al.; TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open. 2019;4(1):73-84. PMID 30868117 · DOI 10.1002/epi4.12286 PubMedDOI

    International registry. Epilepsy in 83.6% (1852/2216); 38.9% had infantile spasms and 67.5% focal seizures. Mean age at diagnosis of spasms 0.4 years; focal seizures 2.7 years (median 1 year). 79.3% of those with epilepsy were diagnosed before age 2. Spasms were more common with TSC2 than TSC1 variants (47.3% vs 23%). GABAergic drugs were the most common treatment for spasms (78.7%) and focal seizures (65.5%). Spasms were controlled in 76.3% and focal seizures in 58.2%. Seizure control was linked to lower rates of intellectual disability. Focal seizures can occur at any age and can come before spasms. Funding: Novartis. ---

Everolimus in tuberous sclerosis complex

  • Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125-132. PMID 23158522 · DOI 10.1016/S0140-6736(12)61134-961134-9) · NCT00789828 PubMedDOI

    Background: TSC leads to "constitutive activation of mammalian target of rapamycin (mTOR) and growth of benign tumours in several organs." SEGA growth can cause hydrocephalus. 117 patients aged 0 to 65 (78 everolimus, 39 placebo). SEGA volume fell by at least 50% in 27 (35%) on everolimus vs none on placebo (p under 0.0001). Most adverse events were grade 1 or 2; most common were mouth ulceration (32% vs 5%), stomatitis (31% vs 21%), convulsion (23% vs 26%) and fever (22% vs 15%). Funding: Novartis.

  • Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817-824. PMID 23312829 · DOI 10.1016/S0140-6736(12)61767-X61767-X) · NCT00790400 PubMedDOI

    Adults (18 and older) with at least one angiomyolipoma 3 cm or larger. 118 randomized (79 everolimus, 39 placebo). Angiomyolipoma response (at least 50% volume reduction) 42% vs 0%. Angiomyolipoma growth can lead to bleeding and impaired kidney function. Most common adverse event: stomatitis (48% vs 8%). Funding: Novartis.

  • French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153-2163. PMID 27613521 · DOI 10.1016/S0140-6736(16)31419-231419-2) · NCT01713946 PubMedDOI

    366 patients aged 2 to 65 with TSC and treatment-resistant focal-onset seizures on 1 to 3 antiseizure drugs. Responders (at least 50% fewer seizures): placebo 15.1%, low-exposure everolimus 28.2%, high-exposure 40.0%. Median seizure reduction 14.9%, 29.3% and 39.6%. Grade 3 or 4 adverse events 11%, 18% and 24%. Funding: Novartis.

  • AFINITOR (everolimus) tablets and AFINITOR DISPERZ (everolimus tablets for oral suspension) prescribing information, revised 6/2026. Source

    §1.4: AFINITOR for "Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery." §1.5: AFINITOR and AFINITOR DISPERZ for "adult and pediatric patients aged 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected." §1.6: AFINITOR DISPERZ "for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures." Dosing for TSC seizures is adjusted to blood trough concentrations of 5 to 15 ng/mL. ---

Seizures in babies

  • Pressler RM, Cilio MR, Mizrahi EM, et al. The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia. 2021;62(3):615-628. PMID 33522601 · DOI 10.1111/epi.16815 PubMedDOI

    "Seizures are the most common neurological emergency in the neonatal period". Unlike those in older children, they are often provoked seizures with an acute cause and "may be electrographic-only". The framework "emphasizes the role of electroencephalography (EEG) in the diagnosis of seizures in the neonate". "Many neonatal seizures are electrographic-only with no evident clinical features." Clinical events without an EEG correlate are not counted. Neonatal seizures have a focal onset, so a focal vs generalized split is unnecessary. Types: motor (automatisms, clonic, epileptic spasms, myoclonic, tonic), non-motor (autonomic, behavior arrest), or sequential.

  • Glass HC, Shellhaas RA, Wusthoff CJ, et al.; Neonatal Seizure Registry Study Group. Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study. J Pediatr. 2016;174:98-103.e1. PMID 27106855 · DOI 10.1016/j.jpeds.2016.03.035 PubMedDOI

    426 consecutive neonates at 7 US centers monitored with continuous video-EEG. Most common causes: hypoxic-ischemic encephalopathy 38%, ischemic stroke 18%, intracranial hemorrhage 11%. 59% had 7 or more electrographic seizures and 16% had status epilepticus; 52% received 2 or more antiseizure medicines. 17% died during the admission. Higher seizure burden was linked to death and abnormal neurological exam at discharge.

  • Acar DB, Bulbul A, Uslu S. Current Overview of Neonatal Convulsions. Sisli Etfal Hastan Tip Bul. 2019;53(1):1-6. PMID 33536818 · DOI 10.14744/SEMB.2018.22844 · PMC7847733 PubMedDOI

    Neonatal convulsions occur in 1.5 to 3 per 1,000 live births. Hypoxic-ischemic encephalopathy is the most common cause. (Full text) Four clinical types: subtle, clonic, tonic, myoclonic. Subtle seizures are the most common and include eyelid tremor, a fixed gaze or horizontal eye deviation, smacking, chewing or other mouth movements, and pedaling movements, often with autonomic signs such as fast heart rate. Clonic: rhythmic jerks 1 to 3 times a second in any part of the body, focal or multifocal. Tonic: sudden increase in muscle tone, usually under a minute, with posturing of trunk, neck or a limb. Myoclonic: rapid isolated jerks of the head or a limb, or of arms and legs together. (Full text) Non-epileptic movements: jitteriness is the most common; it is quick, symmetrical trembling without autonomic signs and can be stopped by passively flexing the limb. Sleep myoclonus happens during sleep and typically stops when the baby wakes. Hyperekplexia is an exaggerated startle response triggered by sound, sight or touch. A newborn with convulsions should be hospitalized and monitored with continuous video-EEG if possible; acute metabolic problems found on rapid evaluation are treated. (Full text, re-checked in PMC7847733) "Jitteriness and sleep myoclonia do not require treatment." Hyperekplexia is described as "a very exaggerated startle response triggered by auditory, visual, or tactile stimulation."

  • Maurer VO, Rizzi M, Bianchetti MG, Ramelli GP. Benign neonatal sleep myoclonus: a review of the literature. Pediatrics. 2010;125(4):e919-e924. PMID 20351003 · DOI 10.1542/peds.2009-1839 PubMedDOI

    Neurologically normal term infants can have "repetitive, rhythmic myoclonic jerks that occur during sleep", traditionally resolved by 3 months with no sequelae. 24 reports, 164 infants. Jerks occurred in all sleep stages, "disappeared after arousal", and could be induced by rocking or repetitive sounds. Abstract wording (re-checked via PubMed efetch): "in affected infants, jerks stopped or even worsened by holding the limbs or on medication with antiepileptic drugs." So holding the limbs does not reliably stop them, and they can get worse; the dependable sign is that they occur only in sleep and stop on waking. It did not resolve by 3 months in one-third of infants.

  • Wheless JW, Gibson PA, Rosbeck KL, et al. Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatr. 2012;12:108. PMID 22830456 · DOI 10.1186/1471-2431-12-108 · PMC3411499 PubMedDOI

    (Full text) Onset in the first year in 90%; peak onset 3 to 7 months. In most cases parents' observation starts the evaluation; episodes may look like colic or be mistaken for reflux. "Parental/caregiver videos of infant spasms may assist with the clinical evaluation." Consultation with a pediatric neurologist is warranted as early as possible if events on video are suspicious. (Full text) Spasms can be subtle, the most subtle being a head nod or eye rolling. Typically brief symmetrical contractions of neck, trunk and limbs lasting up to 5 seconds, in clusters of a few to more than 100; a cluster can last under a minute to more than 10 minutes. A prolonged awake and asleep video-EEG is recommended if spasms are suspected.

  • Huang LL, Wang YY, Liu LY, et al. Home Videos as a Cost-Effective Tool for the Diagnosis of Paroxysmal Events in Infants: Prospective Study. JMIR Mhealth Uhealth. 2019;7(9):e11229. PMID 31516128 · DOI 10.2196/11229 PubMedDOI

    301 practitioners diagnosed 12 infant cases from descriptions alone, then again after watching home videos. Mean correct diagnoses rose from 7.5 to 8.4 of 12. Videos improved accuracy for both epileptic seizures and non-epileptic events. Authors: home videos on mobile phones help diagnose paroxysmal events in infants.

  • Subcommittee on Febrile Seizures; American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127(2):389-394. PMID 21285335 · DOI 10.1542/peds.2010-3318 PubMedDOI

    AAP guideline for simple febrile seizures in children 6 through 60 months. Attention goes to the cause of the fever; meningitis should be considered in any febrile child. A simple febrile seizure does not usually need EEG, blood tests or brain imaging.

  • Febrile seizures. MedlinePlus Medical Encyclopedia (National Library of Medicine). Source

    A temperature of 100.4 °F (38 °C) or above may cause febrile seizures. They occur most often in otherwise healthy children between 6 months and 5 years. A simple febrile seizure stops by itself within a few seconds to 10 minutes. A seizure longer than 15 minutes, in one part of the body, or repeated in the same illness is not a normal febrile seizure. In infants and young children, other causes of a first seizure, especially meningitis, must be ruled out. Further testing may be needed if the child is younger than 9 months. During the seizure: do not hold the child down, do not leave the child alone, lay the child on the ground in a safe area, turn the child to the side if vomiting, and do not force anything into the mouth. "If the seizure lasts several minutes, call 911 or the local emergency number to have an ambulance take your child to the hospital." "If the seizure ends quickly, drive the child to an emergency room when it is over." Simple febrile seizures are harmless; no evidence they cause death, brain damage, epilepsy or learning problems. (Live page, re-checked) During a febrile seizure "The child will not respond to the parent's voice." First aid includes "Loosen tight clothing, especially around the neck." After: "It is normal for children to sleep or be drowsy or confused for a short time right after a seizure."

  • Seizures. MedlinePlus Medical Encyclopedia (National Library of Medicine). Source

    Some seizures have mild symptoms without shaking, and some only cause staring spells that may go unnoticed. Symptoms depend on which part of the brain is involved. Causes include abnormal blood sodium or glucose, brain infection (meningitis, encephalitis), brain injury to a baby during labor or birth, brain problems present before birth, fever (particularly in young children), head injury, and phenylketonuria (PKU), "which can cause seizures in infants". Sometimes no cause is found. (Live page, re-checked) Definition: "A seizure is the physical changes in behavior that occurs during an episode of specific types of abnormal electrical activity in the brain." Symptoms listed include "Drooling or frothing at the mouth", "Eye movements", "Temporary stop in breathing" and "Uncontrollable muscle spasms with twitching and jerking limbs." (Live page, re-checked) First aid includes "Loosen tight clothing, especially around the neck." and "Do not give the person anything by mouth until the convulsions have stopped and the person is fully awake and alert." Call 911 or the local emergency number if it is the first seizure; a seizure lasts more than 2 to 5 minutes; the person does not wake up or return to normal behavior; another seizure starts soon after; the seizure happened in water; or the person is injured. Do not restrain the person or put anything in the mouth.

  • First Aid for Seizures. Centers for Disease Control and Prevention. Source

    Steps: stay calm, stay with the person, remove anything nearby that could cause injury, turn the person gently onto one side with the mouth pointing to the ground, and "Time the seizure to track if it lasts more than 5 minutes. If it does, seek immediate medical attention or call 911." Do not hold the person down or stop their movements; do not put anything in the mouth; do not offer water or food until fully alert. Call 911 if the seizure lasts longer than 5 minutes; another seizure follows soon after; the person has trouble breathing or waking up after the seizure; is injured; the seizure happens in water; or the person "Has never had a seizure before."

  • Epileptic spasms. EpilepsyDiagnosis.org, International League Against Epilepsy (ILAE) diagnostic manual. Source

    "An epileptic spasm is a sudden flexion, extension or mixed flexion-extension of proximal and truncal muscles", lasting 1 to 2 seconds, longer than a myoclonic jerk. "Spasms typically occur in a series, usually on wakening."